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ABSTRACT
The U3 region of long terminal repeat (LTR) of equine infectious anemia virus 
(EIAV) contains transcriptional regulatory elements. To identify the elements in 
prototype (P), fetal donkey dermal cell-adapted (A), and two variant (V) EIAV LTRs, 
DNase I footprinting, gel shift, and transient gene expression assays were performed. 
The assays used U937 monocytic cells which can be induced into macrophages by 
12-0-tetradecanoylphorboI-13-acetate (TPA). For study of API sites, c-Jun/APl was 
also used.
Footprinting with nuclear extracts from TPA-induced and uninduced U937 
cells localized methylated DNA-binding protein (MDBP), PEA2, API, PU.l, and 
CCAAT enhancer-binding protein (C/EBP) sites as common elements in 5' to 3' 
direction in the U3 region of the 4 LTRs. The hypervariable region between the PEA2 
and API sites was footprinted to contain at least one of the PEA2, API, or PU. 1 
elements. In particular, the U3 region of ALTR was footprinted to contain Oct-1, 
MDBP, PEA2, PEA2, API, PU.l, API, PU.l, and C/EBP sites. The Oct-1 motif 
exists only in ALTR. Footprinting of the 4 LTRs with purified c-Jun/APl and gel shift 
assays of oligonucleotides containing LTR API sites with either c-Jun/APl or U937 
nuclear extracts supported the identification of the API sites by the footprinting with 
the nuclear extracts.
Transient gene expression assays of the 4 wild-type LTRs and ALTR mutants 
were performed with TPA-induced and uninduced U937 cells. These assays identified 
the existence of a negative regulatory element (NRE) upstream of the MDBP site.
ix
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With the exception of NRE and the PEA2 and C/EBP elements whose functions were 
not determined, comparison of the activities of the ALTR mutants indicated that all the 
elements contribute positively to both TPA-induced and uninduced basal promoter 
activitites. In addition, this comparison showed that the PU. 1 element is the most 
important for the induced activity. These results suggest that the Oct-1, MDBP, API, 
and PU. 1 elements cooperatively acts for the maximal basal promoter activity in 
monocyte and macrophage cells.
x
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CHAPTER 1 
INTRODUCTION
1.1. Review of Literature
Equine infectious anemia vims (EIAV) belongs to the lentivirus genus of the 
retro vims family, the Retro viridae (Coffin, 1992). Retroviruses acquired their name 
for their ability to reverse the normal flow of genetic information by converting their 
genomic ribonucleic acid (RNA) into a double-stranded (ds) deoxyribonucleic acid 
(DNA). The lentivirus genus includes human immunodeficiency vims (HTV), simian 
immunodeficiency vims (SIV), bovine immunodeficiency vims (BIV), EIAV, visna 
vims, caprine arthritis-encephalitis vims (CAEV), and feline immunodeficiency vims 
(FIV). In this review, some characteristics common to retroviruses will first be 
described, then literature relevant to the present studies of HIV type 1 (HTV-1), the 
most studied lentivirus, as a representative lentivirus will be presented, followed by a 
review of relevant EIAV literature.
1.1.1. Retroviruses
1.1.1.1. Retrovirus Virion Structure
Retrovirus virions are spherical particles 80-130 nm in diameter with an 
internal spherical or conical core (Luciw and Leung, 1992) (Fig. 1). The core 
consisting of a capsid protein (CA) layer and a ribonucleoprotein complex is 
surrounded by a matrix protein (MA) layer and then by a lipid-bilayer envelope. The 
ribonucleoprotein complex is composed of the viral genomic RNA and a nucleoprotein 
(NC) which is a small basic protein. The envelope is derived by budding from the host
1













Fig. 1. Schematic representation of a retrovirus virion.
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plasma membrane and is studded with knob-like structures of two viral glycoproteins, 
the receptor-binding or surface protein (SU) and the transmembrane protein (TM). 
Each virion contains two identical copies of positive-sense single-stranded (ss) RNA. 
The virion RNA molecules are 7-10 kilobases (kb) in length, capped with 
m7G5'ppp5'Gmp at their 5' ends (Coffin, 1990) and polyadenylated at their 3' ends like 
cellular messenger RNAs (mRNAs). A specific cellular transfer RNA (tRNA) 
molecule is base-paired to a sequence of the RNA to serve as primer for reverse 
transcriptase. The primer binding site (PBS) is located 100-500 bases from the 5' end 
of each RNA molecule (Coffin, 1990). CA, MA, and NC are encoded by the gag 
gene, whereas the two envelope glycoproteins are encoded by the env gene. In the 
virion core, there are three essential viral enzymes for retrovirus replication: reverse 
transcriptase (RT) for the conversion of the genomic RNA into a linear 
double-stranded DNA, integrase (IN) for the integration of the proviral DNA into the 
host chromosome, and protease (PR) for cleavage of the gag and pol polyproteins for 
maturation of the viral particle. These enzymes are encoded by the pol gene.
1.1.1.2. Retroviral Life Cycle
The first step in the retroviral life cycle is attachment of the virion through the 
viral envelope surface protein to a specific cell surface receptor. Then, a hydrophobic 
region called the fusogenic domain near the amino terminus of the transmembrane 
protein mediates fusion of the viral envelope with the cell membrane releasing the 
virion core into the cytosol, where additional uncoating events occur (Coffin, 1990). 
The released core decondenses and genomic RNA can be copied into the linear
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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proviral DNA by the viral RT. Retroviral RTs posess 3 enzymatic activities: 
RNA-dependent DNA polymerase, Ribonuclease H, and DNA-dependent DNA 
polymerase activities. These activities catalyze copying of the positive-strand RNA 
genome to produce the negative-strand DNA, digestion of the RNA template, and 
synthesis of the positive-strand DNA using the negative-strand DNA as a template 
(Katz and Skalka, 1994; Arts and Wainberg, 1996). As a consequence of the reverse 
transcription, the resulting proviral DNA contains a long terminal repeat (LTR) at both 
the 5' and 3' ends. These LTRs contain, in the 5' to 3' direction, the U3, R, and U5 
regions of the genomic RNA. Retroviral LTRs contain regulatory sequences such as 
promoter and enhancer sequences for the control of retrovirus gene expression. The 
completed proviral DNA, which is still associated with the core structure, is then 
transported into the cell nucleus and becomes integrated into the host cell 
chromosome by the integrase activity. The integrated proviral DNA is now termed a 
provirus.
Once integrated, the proviral DNA may remain in a latent state or be activated 
and transcribed by host RNA polymerase n. Transcription is initiated at the first 
nucleotide (nt) of the R region, the cap site, and apparently proceeds through the 3' 
LTR into flanking cellular DNA (Coffin, 1990). The primary RNA transcript is 
capped at the 5' end and polyadenylated at the 3' end by cellular systems. This 
full-length viral RNA can remain unspliced, or it may be spliced singly or multiply into 
shorter mRNAs. All these RNAs are transported to the cytoplasm and translated by 
the cellular machinery to produce viral proteins. The unspliced full-length RNA is
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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used to make the Gag and Gag-Pol polyproteins. The spliced mRNAs are used to 
make the Env polyprotein, and in the case of complex retroviruses such as lentiviruses, 
the regulatory and auxiliary proteins (see 1.1.1.3.). The full-length viral RNA as 
genomic RNA may be packaged together with Gag and Gag-Pol polyproteins into the 
capsid. With most virus groups, capsid assembly and budding occurs simultaneously 
at the cell membrane (Coffin, 1990). During or shortly after budding, internal 
cleavage of the polyproteins by the PR and condensation of the core result in 
maturation of the virion (Cullen, 1993).
1.1.1.3. Retroviral Gene Expression
Retroviruses can be divided into two classes, simple and complex retroviruses, 
based on the complexity of genomes and the regulatory pattern of viral gene 
expression (Cullen, 1991). Simple retroviruses include the majority of the 
oncoviruses, but exclude the human T-cell leukemia (or lymphotropic) virus type 1 
(HTLV-1) and related viruses [HTLV-II, simian T-cell leukemia virus (STLV), and 
bovine leukemia virus (BLV)]. The simple retrovirus genomes contain only the 
obligatory gag, pol, and env genes in the same 5' to 3' direction and perhaps an 
oncogene such as src in Rous sarcoma virus (RS V) or a gene, like sag in mouse 
mammary tumor virus (MMTV), which are involved in activating the replication of 
specific target cell subsets. Simple retroviruses depend entirely on cellular proteins to 
regulate the level of proviral transcription and the pattern of viral mRNA processing 
and, therefore, show little or no temporal modulation (Cullen, 1991).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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The complex retroviruses include the remainder of the retroviruses, including 
all lentiviruses and spumaviruses, as well as HTLV-I and related viruses (HTLV-II, 
STLV, and BLV). In addition to the obligatory gag, pol, and env, complex 
retroviruses encode 2 to 6 additional proteins from a variable number of alternatively 
spliced transcripts. These additional proteins are often referred to as the regulatory 
proteins (e.g. Tat, Rev, and Nef) and the accessory proteins (e.g. Vif, Vpu, and Vpr) 
(Cullen, 1991). Complex retroviruses, in contrast to the simple retroviruses, encode 
potent transcriptional Pvmy-activators of their LTR promoter elements. In early 
infection, the provirus gives rise to a low level of viral mRNA transcription that is 
mediated by cellular transcription factors. Once mRNA specific for the transcriptional 
trans-activator like Tat [see 1.1.2.1.(2.2.1.)] is expressed, a positive feed-back loop is 
established, leading eventually to the formation of a high-level of the 
posttranscriptional regulatory protein like Rev [see 1.1.2.1.(2.2.2.)]. Thus, complex 
retroviruses have Tat-mediated transactivation level of gene expression in addition to 
the basal level of gene expression of the simple retroviruses. Then the 'Rev-like' 
protein represses the further synthesis of the multiply-spliced early mRNAs that 
encode the additional proteins and activates the expression of unspliced and 
singly-spliced late mRNAs that encode the viral structural proteins. Thus, the action 
of Rev-like proteins divides the gene expression of complex retroviruses into two 
temporal phases, an early regulatory phase and a later structural phase in which 
structural proteins are synthesized for assembly of progeny virions (Cullen, 1991).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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1.1.2. HIV-1
HIV-1 is the primary etiologic agent of acquired immunodeficiency syndrome 
(AIDS), a fatal disease that results from the progressive depletion of cluster of 
differentiation 4" (CD4~) T lymphocytes (gradual destruction of the helper T-cell 
population) in infected individuals. HIV-1 may be viewed as the prototype of not only 
the lentivirus genus but also, more broadly, complex retroviruses (Cullen, 1992).
1.1.2.1. The Structure of HIV-1 Proviral Genome
HTV-1 proviral genome (Fig. 2) has the most complicated structure among the 
retroviruses. There is a considerable variability in sequence and length between 
individual HTV-1 isolates, particularly in the LTR and the env gene regions. For 
convenience the genome structure of the ARV-2/SF2 isolate (Sanchez-Pescador et 
al., 1985; GenBank database accession: K022007), a typical HTV-1 strain, is described 
here. The proviral genome of this isolate is 9,736-base pairs (bp) in length.
(1.) The HIV-1 LTR
The HTV-1 proviral genome contains at both 5' and 3' ends each a 634 bp-LTR 
consisting of 453-bp U3, 97-bp R, and 84-bp U5 regions. Transcription starts from 
the first nt of 5' R region and continues to the last nt of 3' R region.
The HTV-1 LTR is an extremely complex regulatory element that contains 
binding sites for a variety of cellular transcription factors in the 5' to 3' direction: three 
potential sites for activator protein 1 (API), one site for chicken ovalbumin upstream 
promoter transcription factor (COUP-TF), two sites for nuclear factor of activated T 
cell (NF-AT), one site for upstream binding/stimulatory factor (USF), one site for
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Fig. 2. Structure of HTV-1 proviral DNA. The sequence of an HIV-1 isolate, 
ARV-2/SF2 (Sanchez-Pescador et al., 1985), was used. The abbreviations used 
are: LTR, long terminal repeat; TAR, /raws-activation responsive element; RRE, 
Rev response element.
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T-cell factor l a  (TCF-la), two sites for nuclear factor of kappa B cells (NF-kB), 
three sites for Spl, one site for untranslated binding protein 1 (UBP-l)/leader binding 
protein 1 (LBP-1), one site for TATA-binding protein (TBP) flanked by two 
functional consensus E box sequences (Ou et al., 1994), one site for initiator (INT), 
two sites for UBP-1/LBP-1, one site for untranslated binding protein 2 (UBP-2), and 
one site for CAAT transcription factor (CTF)/nuclear factor 1 (NF1) (Antoni et al., 
1994; Nabel, 1993; Ou and Gaynor, 1995).
The upstream elements of the NF-kB sites (API, COUP-TF, NF-AT, USF, 
and TCF-la sites) compose HTV-1 modulatory region from nt -454 to -122. Deletion 
of the modulatory region from API to USF sites resulted in increased basal and 
Tat-mediated gene expression and increased viral replication in lymphoid (Jurkat) and 
myeloid (U937) cell lines (Lu et al., 1989; Ou and Gaynor, 1995). The modulatory 
region contains both positive- and negative-acting c/s-regulatory elements. The 
negative effect of the deleted region, however, did not depend on the nef gene (Lu et 
al., 1989). HTV-1 gene expression can be affected by mutations of the binding sites in 
the modulatory region, but is not totally eliminated either in the presence or in the 
absence of the transactivator, Tat (Ou and Gaynor, 1995). Evidently, many cellular 
factors can bind to this region and modulate HTV-1 gene expression in response to 
diverse extracellular signal transduction pathways including those regulating cellular 
differentiation and T-cell activation (Ou and Gaynor, 1995).
The two NF-kB sites compose the HTV-1 enhancer region from nt -109 to -79. 
Each site contains a 10 bp conserved sequence (GGGACTTTCC), known as NF-kB
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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motif. These NF-kB sites are essential for inducible gene expression by the HTV-1 
enhancer in a variety of different cell lines, particularly in T cells. Mutations of the 
NF-kB sites abolish the ability of NF-kB transcription factor to bind to the sites and 
have deleterious effects on viral gene expression. In addition to the NF-kB 
transcription factor, thyroid hormone receptor and Ets-1 proteins can also bind to 
these sites. Furthermore, NF-kB and Spl cooperatively bind to the LTR, indicating 
that there is functional synergism between the HTV-1 enhancer and core promoter 
region (Nabel, 1993; Ou and Gaynor, 1995).
The binding sites for Spl, UBP-l/LBP-1, TBP, and TNT (Jones, K. A. et al., 
1988) compose the HIV-1 core promoter region from nt -78 to -1. The core region is 
critical for both basal level and Tat-induced transcription. Spl is a ubiquitous 
mammalian transcription factor that contains three zinc finger motifs. Zinc finger 
proteins can bind the GC box sequence, GGGCGG (Ou and Gaynor, 1995; Antoni et 
al., 1994). It has been shown that Spl can activate transcription from viral and 
cellular genes that have one or more GC-boxes within the promoters (Briggs et al., 
1986). Mutations of any two of three Spl sites in the HTV-1 LTR resulted in minimal 
decreases in both basal level and Tat-induced transcription in transfection studies 
(Harrich et al., 1989). Proviral studies showed that maintenance of the Spl sites is 
absolutely required for viral replication and growth. The 110-kDa TATA-binding 
protein (TBP)-associated factor (TAF110) can mediate transcriptional activation of 
Spl by directly interacting with Spl to bridge the gap between Spl and the 
transcription factor IID (TFUD) complex (Hoey et al., 1993; Ou and Gaynor, 1995).
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Spl and Tat can directly interact, suggesting that Tat can facilitate the assembly of the 
preinitiation complex through its interaction with Spl. Thus, it is possible that Tat in 
combination with TAF110 may act to bridge Spl and TFllD (Jeang et al., 1993; Ou 
and Gaynor, 1995). The distance between the three Spl sites and the TATA box is 
also important for both Tat-mediated transactivation and for viral growth (Ou and 
Gaynor, 1995). Transcriptional activation by DNA replication has been reported for a 
number of cellular and viral promoters, although the mechanism is not clear. Spl can 
also mediate transcriptional activation of HTV-1 LTR promoter by DNA replication 
via its activation domain without Tat. In the presence of Tat, the replication-mediated 
transcriptional activation is further activated principally at the level of processivity 
(Williams et al., 1996). Perkins et al. (1993) showed that the optimal HIV-1 enhancer 
function requires the synergistic and cooperative binding between Spl and NF-kB 
proteins. The functional role of the UBP-l/LBP-1 has been contradictary and remains 
to be elucidated (Antoni et al., 1994).
The TATA box is directly bound by the 38-kDa TBP of a complex of cellular 
factors termed TFUD (Rigby, 1993). TFHD contains, in addition to TBP, at least 
eight TAFs (Jones and Peterlin, 1994). Though the roles of most TAFs have yet to be 
demonstrated, they appear to mediate interactions between TBP and either upstream 
or downstream DNA-binding factors. TAF110 mediates interactions between Sp 1 and 
TBP (Hoey et al., 1993), and TAF250 modulates TBP activation (Weinzierl et al., 
1993; Ou et al., 1994). The TATA element has been demonstrated to be critical for 
basal and Tat-induced HIV-1 gene expression. Mutations in the TATA element
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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dramatically decreased both basal and Tat-induced HIV-1 gene expression. Mutating 
the HTV-1 TATA and flanking sequences to sequences found in other viral and cellular 
promoters altered both basal and Tat-induced gene expression of HTV-1 (Ou and 
Gaynor, 1995). The HTV-1 TATA sequence is flanked by two functional consensus E 
box sequences. Mutagenesis of the flanking E boxes singly or in combination or 
substituting other viral promoter sequences flanking the TATA box, also severely 
decreased both basal and Tat-induced gene expression in transfection and in vitro 
transcription assays (Ou et al., 1994).
The initiator element was originally identified as a sequence motif surrounding 
the transcriptional initiation site in the terminal deoxynucleotidyl transferase (tdt) gene 
that lacks a TATA box. This initiator sequence helps to specify the transcriptional 
initiation site in the tdt gene (Smale and Baltimore, 1989; Smale et al., 1990; Ou and 
Gaynor, 1995). Initiator elements are also found in promoters containing TATA 
boxes where the initiator element functions primarily to regulate the degree of 
promoter activity. So far, at least four different proteins have been demonstrated to 
bind to various initiator elements, and three of them [Yin and Yan 1 (YY1), USF, and 
transcription factor (TFII-I)] to the sequences surrounding the HIV-1 transcriptional 
initiation site (Ou and Gaynor, 1995).
The elements downstream of the ENT site (UBP-1/LBP-1, UBP-2, and 
CTF/NF1 sites) compose HTV-1 TAR region from nt +1 to +60. Deoxyribonuclease 
(DNase) I footprinting and gel shift assays indicate that many cellular factors bind to 
TAR DNA element. Mutations of these binding sites in TAR DNA result in modest
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decreases in HIV-1 gene expression (Jones, K. A., et al., 1988; Ou and Gaynor,
1995). However, the functions of these factors in HIV-1 gene expression still remain 
to be elucidated. TAR RNA rather than TAR DNA binds Tat and acts for 
Tat-mediated transactivation [see 1.1.2.1.(2.2.1.)].
(2.) The Genes of HIV-1
The 5' LTR is followed by an untranslated region from nt 635 to 789 between 
U5 and gag gene initiation codon, and then by the three structural genes (gag, pol, and 
env) for encoding virion proteins like other retroviruses. HTV-1 also includes at least 
six additional genes coding three regulatory and three accessory proteins which are 
important in virus replication, particularly in the regulation of expression. The three 
regulatory proteins (Tat, Rev, and Nef) are early gene products synthesized from 
Rev-independent multiply spliced mRNAs of (about 2 kb) and play strong regulatory 
roles, while the three accessory proteins (Vif, Vpr, and Vpu) are late viral proteins 
expressed from Rev-dependent singly spliced mRNAs (about 4 kb) and function in the 
morphogenesis and release of HTV-1 virions (Peterlin, 1995; Cullen, 1991). Each gene 
has its own translational initiation codon except for pol gene which is expressed by 
translational frameshifting of gag gene.
(2.1.) The Three Structural Genes of HIV-1
There are three major genes coding for structural proteins (Fig. 2). The 
1509-bp gag gene from nt 790 to 2298 encodes the core proteins, pi 7 (MA), p24 
(CA) which is the most abundant protein, p9 (NC), and p7 (proline-rich protein) 
(Peterlin, 1995). The 3012-bp pol gene from nt 2091 to 5102 directs the synthesis of
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protease (PR), reverse transcriptase (RT) with ribonuclease H (RNase H) activity, and 
integrase (IN). The 2568-bp env gene from nt 6232 to 8799 encodes the two 
envelope glycoproteins, gpl20 (SU) and gp41 (TM).
(2.2.) The Three Regulatory Genes of HIV-1 (tat, rev, and nef) 
(2.2.1.) HIV-1 tat Gene
HTV-1 Tat (trans-activator of transcription) protein is a prototype of a group 
of lentivirus Tat proteins which strongly transactivate their viral LTRs upon binding to 
their TAR RNAs. This group contains the Tat proteins of HTV-1, HTV-2, STV, BTV, 
and EIAV. The second group consists of the Tat proteins of FTV, visna virus, and 
CAEV, which weakly transactivate their LTRs and do not possess a TAR sequence 
(Harmache et al., 1995; Clements and Payne, 1994). Below is the description about 
HIV-1 Tat unless indicated otherwise.
There are two types of functional HTV-1 Tat proteins (72 or 86 amino acids) 
and these are encoded by the first coding exon from nt 5839 to 6053 only or together 
with the second coding exon from nt 8383 to 8428 (Fig. 2). Tat is an RNA-binding 
early framactivator necessary for virus replication. The degree of Tat activation varies 
in different cell types from 40- to 3000-fold (Antoni et a l, 1994). Higher degrees of 
activation are seen in the presence of lower basal transcription rates, and less 
activation is observed if the basal levels are higher. This suggests that Tat acts to 
maximize HIV-1 LTR-directed transcription (Antoni et a l, 1994). Although initial 
studies suggested that Tat had both transcriptional and posttranscriptional effects, 
more recent results revealed that the predominant effect of Tat is at the level of
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activation of RNA transcription (Antoni et al., 1994; Clements and Payne, 1994). 
Although Tat can increase the efficiency of transcriptional elongation and initiation, 
the major function of Tat is to stimulate gene expression by increasing the efficiency in 
transcriptional elongation (Feinberg et al., 1991; Graeble et al., 1993; Williams et al., 
1996).
The transcriptional activation of the HTV-1 LTR is mediated by binding of the 
Tat protein to its target sequence called TAR (Fig. 2), an RNA stem-loop structure 
from nt +1 to +59 located near the 5' end of all nascent HTV-1 transcripts. Although 
the exact mechanism by which Tat activates gene expression is not known, binding of 
Tat and cellular factors to the region of TAR RNA between +18 to +44 is critical.
TAR RNA forms a stable stem-loop structure with a three-nucleotide bulge (+23 to 
+25) and a six-nucleotide loop (+30 to +35) which are essential for Tat-mediated 
activation. The Tat protein binds to the bulge region, while cellular factors such as 
TARRNA-binding protein-185 (TRP-185), cofactors of TRP-185, and a 68-kDa 
cellular protein (p68) bind to the loop region of the TAR RNA. TRP-185 can activate 
Tat-induced transcription but not basal HTV-1 LTR transcription, although it is not 
clear whether it stimulates transcriptional initiation or elongation (Sheline et al., 1991; 
Ou and Gaynor, 1995). The p68 protein binds the loop and increases levels of 
Tat-mediated activation (Peterlin et al., 1993). In addition, a 36-kDa stem-binding 
protein binds to the double-stranded 4-bp stem region between the bulge and the loop 
of the TAR RNA (Antoni et al., 1994). Its binding depends on both the sequence and 
the structure of the TAR stem region and it may play a role in HIV-1 activation
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(Antoni et al., 1994; Ou and Gaynor, 1995). Another stem-binding protein (140 kDa) 
binds to the long stem located before the three-nucleotide bulge in a 
phosphorylation-dependent manner for Tat transactivation (Antoni et al., 1994). The 
requirement that the TAR element be located downstream of the RNA initiation site 
and maintain a specific orientation suggests that the nascent TAR RNA may be the 
major target for Tat-mediated activation (Ou and Gaynor, 1995). In addition, Tat has 
been demonstrated to interact with Spl and TFIID [see 1.1.2.(1.); Jeang et al., 1993; 
Kashanchi, 1993],
Tat protein can also be released into the extracellular fluid from infected T cells 
and has biological activity on uninfected cells (Ensoli et al., 1990; Ensoli et al., 1993). 
Such extracellular Tat causes toxicity in neural and glial cells (Magnuson et al., 1995; 
Nath et al., 1996; Sabatier et al., 1991), and it increases both NF-kB binding and 
protein kinase C activity in astrocyte cells (Conant et a l, 1996). Extracellular Tat can 
also act as a growth factor for cytokine-activated vascular cells and Kaposi's sarcoma 
of AIDS patients (Barillari et al., 1993; Ensoli et al., 1994), and it may increase the 
frequency and aggressiveness of Kaposi's sarcoma in HTV-1 infected people. It has 
been demonstrated that HTV-1 tat gene, under the control of the viral LTR, induces 
both liver cancer and skin lesions (Vogel et a l, 1991; Vogel et al., 1988). HTV-1 Tat 
protein can also induce programmed cell death, apoptosis, in a T cell line and in 
cultured peripheral blood mononuclear cells (Chiang et al., 1995; Li et al., 1995).
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(2.2.2.) HIV-1 rev Gene
Rev (regulator of expression of virion proteins) of 116 amino acids (19 kDa) is 
encoded by the two coding exons (nts 5978 to 6053, and nts 8383 to 8657). Rev 
functions by binding to RRE which is a 234-nt long RNA structure located at the 
junction of the SU and TM sequences of env region (Fig. 2). RRE is composed of 
four RNA stem-loops on a long stable stem (Peterlin, 1995). Transactivation by the 
Rev protein is essential for the expression of viral structural proteins and thus for 
HTV-1 replication. Rev acts posttranscriptionally to facilitate the transport of 
full-length and singly-spliced viral mRNAs which code for structural proteins out of 
the cell nucleus. Rev increases the cytoplasmic level of these transcripts either by 
directly interacting with the splicing system to block splicing (Chang and Sharp, 1989; 
Chang and Sharp, 1990), or by increasing the efflux of the viral transcripts out of the 
nucleoplasm, where they are susceptible to being spliced (Emerman et al., 1989;
Felber et al., 1989; Michael et al., 1995b). In the absence of Rev, the unspliced and 
singly spliced HTV-1 mRNAs are sequestered in the nucleus (Emerman et al., 1989; 
Felber et al., 1989; Hammarskjold et al., 1989; Malim et al., 1989), are unstable 
(Felber et al., 1989; Malim and Cullen, 1993), and are not translated into proteins 
(Arrigo and Chen, 1991; DAgostino et al., 1992; Lawrence et al., 1991; Tan et al.,
1996).
(2.2.3.) HTV-1 nef Gene
Nef (negative factor) of 210 amino acids is encoded by the region from nt 8801 
to 9433 overlapping 332 bp with 3' LTR region from nt 9102 to 9735. HTV-1 Nef
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was initially identified as a negative regulator in viral expression, but the majority of 
recent data support a positive role for Nef (Ou and Gaynor, 1995). Intensive efforts 
have focused on the role of the nef gene in HIV-1 pathogenesis since Kestler et al. 
(1991) demonstrated that /^defective SIV causes reduced virulence in primates. Nef 
has been shown to down-regulate levels of CD4, the primary cell surface receptor for 
HTV-1, by inducing endocytosis of CD4 and thus its subsequent lysosomal degradation 
(Aiken et al., 1994). Recently, Deacon et al. (1995) reported that Nef plays a critical 
role in progression to AIDS, because people infected with nef gene-deleted HTV-1 
have not developed AIDS for a long time (about 12 years). However, other work 
does not support a strict correlation between the structure or function of Nef and the 
rate of HIV disease progression (Michael et al., 1995a; Artenstein et al., 1996). Thus, 
the functional role of Nef in HTV pathogenesis is not clear, and further studies are 
required to identify the mechanisms of Nef action in progression to AIDS.
(2.3.) The Three Accessory Genes of HIV-1 (vif vpr, and vpu)
Vif (virion mfectivity factor) of 192 amino acids (23-kDa basic protein) is 
encoded by the region from nt 5047 to 5625. The vif gene is encoded by all 
lentiviruses except EIAV (Oberste and Gonda, 1992). Deletions in the vif gene have 
been associated with a reduction or loss of viral infectivity (Kishi et al., 1992). Vif 
protein is incorporated into progeny virions, but its biochemical function is still unclear 
(Karczewski, M. K., and K. Strebel, 1996).
Vpr (viral protein R) of 97 amino acids (15 kDa protein) is encoded by the 
region from nt 5565 to 5858. At least one homologue of vpr gene is present in all
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primate Ientiviruses. Vpr is incorporated into virions at molar ratios equivalent to the 
Gag proteins, and the incorporation is determined by a C-terminal region of the p6 
domain of the Gag polyprotein (Cohen et al., 1990; Kondo and Gottlinger, 1996).
Vpr is dispensable for viral replication in most cell lines but not in primary cells, 
particularly in nondividing cells such as macrophages. This could be due to effects of 
Vpr and MA on the nuclear import of uncoated viral complexes (Peterlin, 1995; Gallay 
et al., 1996). In addition, it has been shown that Vpr can activate transcription 3- to 
10-fold from the HTV-1 LTR as well as various heterologous promoters (Peterlin, 
1995).
Vpu (viral protein U) of 81 amino acids (16 kDa protein) is encoded by the 
region from nt 6070 to 6314 (one nt appears to be missing compared with the isolates 
in Ratner et al., 1985). This region overlaps by 83 bp with env gene. Vpu is a 
transmembrane phosphoprotein which is coordinately synthesized with HTV-1 gpl60 
from the same bicistronic mRNA (Schwartz et a l, 1990). The vpu gene is present 
only in HTV-1 (not in HTV-2) and STV^, the simian immunodeficiency virus isolated 
from a chimpanzee (Huet et a l, 1990; Peterlin, 1995). Vpu protein is not found in 
virions (Terwilliger et al., 1989; Schwartz et al., 1990). Vpu has two distinct 
biological activities. One is to enhance the release of virus particles from the plasma 
membrane, and the other is to induce the proteolysis of CD4 in the endoplasmic 
reticulum (ER). CD4 degradation reduces the number of gpl60-CD4 complexes 
which are trapped in the ER and thus facilitates transport and processing of the 
envelope gpl60 glycoprotein precursor (Peterlin, 1995; Schubert et al., 1996).
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1.1.2.2. HIV-1 Cell Tropism
HIV-1 infects T lymphocytes, monocytes/macrophages, dendritic cells and 
microglial cells (Gartner et al., 1986; Weissman et al., 1995). All of these cells 
express the CD4 glycoprotein (Dalgleish et al., 1984; Klatzmann et al., 1984; Maddon 
et al., 1986; Choe et al., 1996). Monocytes/macrophages play an important role in 
HTV-1 pathology because these cells can harbor the HTV-1 with less cytopathology 
and thus may act as a reservoir for the virus (Ho et al., 1986; Gartner et al., 1986; 
Mikovitz et al., 1990).
HTV-1 infects cells expressing CD4 as the primary receptor and at least one of 
the newly described coreceptors as the second receptor on the cell surface. Although 
CD4 binds tightly to HIV-1 gpl20, subsequent fusion of viral and host cell 
membranes needs help of a coreceptor to complete viral entry process. There are two 
kinds of coreceptors, which were discovered recently. The first is called fusin (Feng et 
al., 1996) for the viral entry of T cell line (T)-tropic strain, and the second designated 
as cysteine-cysteine chemokine receptor 5 (CC-CKR-5) for macrophage (M)-tropic 
strain (Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Doranz et al., 1996; 
Dragic et al., 1996). Although CC-CKR5 appears to be the major HTV-1 coreceptor 
for M-tropic isolates, other chemokine receptors such as chemokine receptor 2B 
(CKR-2B) and chemokine receptor 3 (CKR-3) may also be used (Bates, 1996). As 
the viral determinants for HIV-1 cell tropism, the domain between variable regions V4 
and V5 of gpl20 for CD4-binding (Peterlin, 1995), and V3 domain of gpl20 for 
coreceptor use (Bates, 1996) are now understood.
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1.1.3. Equine Infectious Anemia Virus
EIAV is similar to other lentiviruses in virion structure, genome organization, 
cell tropism, and gene expression strategy (Montelaro et al., 1993; Clements and 
Payne, 1994).
1.1.3.1, Equine Infectious Anemia (EIA), the Disease
EIA, also called swamp fever, was first described as an equine infectious 
disease in 1843 (Lignee, 1843), and it is caused by a filterable agent (Vallee and Carre, 
1904). Thus, EIA is the first animal disease to be assigned a viral etiology, preceding 
the identification of Rous sarcoma virus in chicken serum filtrates (Rous, 1911). EIA 
affects all members of the horse family (Equidae) throughout the world (Issel and 
Coggins, 1979). In transmission of EIAV, blood from persistently infected horses is 
the most important source, and the infected blood is transferred principally by 
blood-sucking insects, especially horse flies. Mosquitoes do not appear to be an 
efficient vector (Montelaro et al., 1993). EIA is generally diagnosed by an agar gel 
immunodiffusion (AGID) test, commonly referred to as the Coggins test (Coggins et 
al., 1972), in conjunction with a competitive enzyme-linked immunosorbent assay 
(C-ELISA) as the basis for disease control measures of United states Department of 
Agriculture (Montelaro et al., 1993; Sellon et al., 1994). Although the disease course 
of EIA is variable depending on the dose and virulence of the virus strain and the 
susceptibility of the individual horse, it may include three characteristic stages: acute 
(defined as the first clinical episode), chronic, and inapparent (Issel and Coggins,
1979) (Fig. 3).
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Fig. 3. Schematic representation of the clinical response of an EIAV-infected horse. 
All sustained rectal temperature recordings above 39 °C are considered EIA-associated 
febrile episodes.
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Acute EIA is most often associated with the first exposure to a virulent strain 
of EIAV. It is characterized by fever, thrombocytopenia, anorexia, and pronounced 
viremia as a result of extensive viral replication in peripheral and tissue macrophages 
(Issel and Coggins, 1979; Montelaro et al., 1993). Acute EIA usually occurs within 5 
to 30 days postinfection and lasts only for a few days (Cheevers and McGuire, 1985). 
This rapid onset of EIA is unique among lentiviral symptoms. In some horses (<5%), 
the febrile period is prolonged and the horse may develop a particularly severe and 
often fatal form of EIA characterized by prolonged viremia, severe anemia, ventral 
edema, anorexia, and weight loss (Sellon et al., 1994; Montelaro et al., 1993). 
Naturally infected horses seldom die during the first febrile episode. Among the 
horses that do recover from the acute EIA, a few animals may develop an inapparent 
infection, but more than 95% of the animals progress to the chronic stage of EIA 
(Sellon et al., 1994; Montelaro etal., 1993).
Chronic EIA is characterized by recurring cycles of viremia and associated 
clinical symptoms including fever, thrombocytopenia, anorexia, edema, leukopenia, 
anemia, hemorrhages, diarrhea, glomerulonephritis, lethargy, and weight loss (Sellon 
et al., 1994; Montelaro et al., 1993). The recurrent disease episodes during chronic 
EIA can produce an overall "wasting" condition similar to the clinical manifestations 
observed with HIV and other lentiviral infections. Each clinical episode lasts for 3 to 5 
days, and the interval between disease cycles is irregular, ranging from weeks to 
months (Montelaro et al., 1993). Each febrile episode is associated with a novel
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predominating antigenic variant containing mutations in the gp90 surface envelope 
gene (Kono et al., 1973).
The chronic stage usually ends approximately a year after infection. At this 
time, greater than 90% of horses with chronic EIA become clinically quiescent and 
inapparent carriers of the virus for the remainder of their lives. However, these 
animals continue to harbor EIAV, and the disease can be induced by stress or by 
administration of an immunosuppressant (Kono et al., 1976; Montelaro et al., 1993). 
Suppression of the immune system is a common aspect of the retroviral pathogenesis 
in both man and animals (Newman et al., 1991).
1.1.3.2. EIAV Proviral Genome and Its Protein Products
The EIAV proviral genome (Fig. 4) is similar to but relatively shorter and 
simpler than that of HTV-1, in that it is only 8.2-kb (rather than 9.7 kb) long and 
contains only three (rather than six) additional genes in addition to the obligatory gag, 
pol, and env genes. Here, one of the complete EIAV proviral sequences which are 
available through the GenBank database (accession: M16575; Kawakami et al., 1987) 
is described as a representative isolate. The proviral genome of this typical EIAV 
isolate is 8,229 bp in length.
This EIAV proviral genome contains a 321-bp LTR at both 5' and 3' ends. The 
LTR consists of 209-bp U3, 76-bp R, and 36-bp U5 regions. EIAV LTR is described 
in detail in section 1.1.3.6 . The S' LTR is followed by a leader region of 143 bp from 
nt 322 to 464 between the U5 end and gag gene initiation codon. This leader region 
contains a splice donor site (nt 460) that allows RNA splicing of the leader sequence













Fig. 4. Structure of EIAV proviral DNA. The sequence of an isolate (GenBank 
accession: M16575; Kakami et al., 1987) was used. The abbreviations used are: LTR, 
long terminal repeat; TAR, fraws-activation responsive element; RRE, Rev response 
element.
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to all EIAV RNAs. It also contains the first exon (termed tat-1) of EIAV tat gene 
from nt 373 to 459 capable of encoding 29 amino acids.
Following the leader is the ATG initiation codon of the 1461-bp gag gene from 
nt 465 to 1925. The gag gene encodes a 55-kDa precursor polyprotein (PrSS8*8) 
which yields the core proteins, pl5 (MA), p26 (CA), pi 1 (NC), and p9 (function 
unknown). Overlapping the gag gene by 244 bp is the 3441-bp pol gene open reading 
frame (ORF) from nt 1682 to 5122 in -1 reading frame compared to gag reading frame 
by ribosomal frameshifting (Montelaro et al., 1993). However, the precise beginning 
site of the pol gene is not known. The pol gene encodes EIAV protease, reverse 
transcriptase with RNase H activity, deoxyuridine triphosphatase (dUTPase), and 
integrase. The ubiquitous enzyme dUTPase is encoded by non-primate lentiviruses 
such as EIAV, visna, CAEV, and FIV (Elder et al., 1992; Threadgill et al., 1993).
The dUTPase hydrolyzes deoxyuridine triphosphate (dUTP) and provides 
deoxyuridine monophosphate (dUMP) as a substrate for thymidylate synthase and 
maintains low dUTP/dTTP (deoxythymidine triphosphate) ratios, protecting against 
uracil incorporation into DNA (Komberg and Barker, 1991). It has been suggested 
that these viruses encode dUTPase for the establishment of infections in cell types with 
low cellular dUTPase activity such as monocyte/macrophage lineage (Threadgill et al.,
1993).
Immediately following the pol gene is the second exon (termed tat-2 from nt 
5135 to 5275) of tat gene. This exon which is capable of encoding 46 amino acids is 
included in the so-called ORF SI from nt 5123 to 5275 for "short first ORF" (Rushlow
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et al., 1986) which contains a splice acceptor site at nt 5134. Therefore, EIAV Tat 
protein consists of 75 amino acids from the two in-frame exons, tat-1 and tat-2. EIAV 
Tat protein is functionally homologous to the HTV-1 Tat protein in that it binds TAR 
and acts as a potent transcriptional /ransactivator of LTR-directed transcription (Dorn 
et al., 1990; Noiman et al., 1990). Following tat-1 and 7-bp untranslated region is the 
201-bp long ORF S2 from nt 5283 to 5483 which could potentially yield a 65-amino 
acid protein initiating from the second codon (ATG). No function has yet been 
assigned to ORF S2 protein. Overlapping the ORF S2 by 171 bp is the 2580-bp env 
gene from nt 5312 to 7891 in an alternative reading frame. The env gene encodes a 
135-kDa precursor polyprotein (gpl35) which yields gp90 (SU) and gp45 (TM). The 
first exon (termed rev-l from nt 5437 to 5537) and the second exon (termed rev-2 
from nt 7243 to 7641) of the rev gene lie within the env gene and are in-frame with 
each other but out-of-frame with either env or ORF S2. The rev-1 and rev-2 
sequences are capable of encoding 30, and 132 amino acids, respectively. The rev-2 is 
included in so-called ORF S3 from nt 7234 to 7641. EIAV Rev protein is functionally 
homologous to the HTV-1 Rev protein in that it binds RRE and facilitates nuclear 
transport of full-length and singly spliced viral RNAs encoding virion structural 
proteins (Martarano et al., 1994). If tat-1 is directly spliced to rev-2, rev-2 becomes 
in-frame with env and the result is the production of a chimeric protein between Tat 
and TM proteins which is termed Ttm of 27 kDa. Ttm has been detected in 
EIAV-infected cells, its role has been speculated to be involved in the EIAV life cycle 
since the carboxy terminus of lentiviral TM proteins influences viral infectivity, growth
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
28
kinetics, and cytopathology (Beisel et al., 1993). Between the stop codon of env and 
the 3' LTR is a 17-bp region corresponding to polypurine tract from nt 7890 to 7907 
which contains the initiation site for synthesis of the positive strand of viral DNA 
(Coffin, 1990).
The 25-base-long EIAV TAR from nt 209 to 233 (i.e., +1 to +25) (Carvalho 
and Derse, 1991; Derse et al., 1993; Hoffinan and White, 1995) is produced from the 
5'-portion of R region of 5' LTR like HTV-1 TAR, but it is shorter and simpler in the 
secondary structure. EIAV RRE has not yet been precisely defined. Two separate 
regions of the env gene (nts 5337 to 5552, and nts 7241 to 7713) have been suggested 
to contain EIAV RRE (Martarano et al., 1994).
1.1.3.3. EIAV Cell Tropism
Lentiviruses commonly infect cells of the monocyte/macrophage lineage as a 
major host cell for replication in vivo (Narayan and Clements, 1990). A subset of 
lentiviruses that cause immune deficiency disease (HTV, STV, and FTV) also infect 
CD4* T cells (Onuma et al., 1992; Clements and Payne, 1994). Infection of immune 
cells, particularly the macrophage, is the basis for the multi-organ disease seen in all 
lentiviral infections (Narayan and Clements, 1990; Clements and Payne, 1994). 
Lentivirus spreads to the multiple organs via infected monocytes that do not express 
the virus. Monocytes traffic to the brain, lung, joints, and other organs where they 
mature into macrophages. Then, differentiation of the macrophage activates viral gene 
expression, and virions are produced in the infected organs (Clements and Payne,
1994). Increase in viral expression as monocytes differentiate into macrophages has
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been demonstrated in CAEV (Narayan et al., 1983), visna virus (Gendelman et al., 
1986), and EIAV (Maury, 1994; Sellon etal., 1996). However, HTV-1 infection may 
be more productive in undifferentiated monocytes than in mature macrophages (Kazazi 
et al., 1989). Purified peripheral blood CD4+ monocytes inoculated with HTV-1 in 
suspension produced only low levels of virus even after the cells were differentiated 
into macrophages (Levy, 1993). In differentiated macrophages, HTV-1 transcription 
occurs but transcripts accumulate in the cytoplasm to a high level, but fail to produce 
progeny virions (Pauza et al., 1988; Shattock et al., 1993; Sellon et al., 1996).
EIAV shares the lentiviral tropism for cells of the monocyte/macrophage 
lineage. The primary target cells of EIAV infection in horses are leukocytes in the 
monocyte/macrophage lineage. Although undifferentiated monocytes are permissive 
for EIAV infections, viral replication appears restricted as in visna virus infection 
(Sellon et al., 1994). Lymphocytes do not appear to be a target for EIAV replication 
in vivo (Montelaro et al., 1993). The determinants for the EIAV cell tropism remain 
to be determined. A recent study of EIAV replication in vitro suggests that the gp90 
env gene region of the virus is not an important determinant for EIAV cell tropism, at 
least in vitro (Perry et al., 1992). The primary sites of EIAV replication during febrile 
episodes are macrophages: viral antigens are detected in all organs and tissues in which 
macrophages are found, and virus titers are highest in organs with the largest numbers 
of monocytes/macrophages (McGuire et al., 1971; Rice et al., 1989; Sellon et al,
1992). It has not been possible to consistently detect viral antigen or DNA in tissues
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of peripheral blood leukocytes during afebrile periods both in chronic and inapparent 
stages (Montelaro et al., 1993).
I.I.3.4. EIAV Strains
Here, EIAV strains along with cell cultures are briefly described. Many strains 
of EIAV have been described in EIAV literature. They are markedly different in cell 
culture characteristics, infectivity, and virulence. Virulent field/wild-type isolates [e.g., 
Wyoming wild type strain (Wyo-EIAV)] of EIAV cannot be propagated in 
tissue-culture cell lines, but only in primary horse macrophage cultures (HMCs). But 
primary HMCs are difficult to maintain for any extended time. In vitro infection of 
primary HMCs with a wild-type EIAV causes a cytopathic effect (CPE) as early as 72 
hour post-infecton. The CPE is similar to normal cellular senescence (Sellon et al.,
1994).
The Wyo-EIAV originated from a horse in Wyoming experiencing a febrile 
episode of EIA (Kemeny et al., 1971). The cell-adapted strain of Wyo-EIA, called 
Malmquist strain of EIAV, the prototype EIAV, or the prototype Wyoming isolate of 
EIAV, was derived by multiple passage of the Wyo-EIAV in equine dermal cells 
(Malmquist et al., 1973; Orrego et al., 1982). The Malmquist strain can infect the 
equine dermal cells and produce infectious progeny virions. However, the equine 
dermal cells infected by the Malmquist strain do not show CPE (Malmquist et al., 
1973). Virulence of the Malmquist strain is severely attenuated in vivo, but it can be 
regained after serial backpassage in horses without a concomitant loss of infectivity 
(Orrego etal., 1982; Gutekunst et al., 1979). Perry et al., (1992) reported that
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wild-type EIAV is unable to perform an early event(s) in EIAV replication 
(attachment, penetration, and/or reverse transcription) in equine dermis and canine cell 
cultures. However, the virulence factors for EIAV remain to be determined, as in 
other lentiviruses.
The propagation of the Malmquist strain in primary fetal equine kidney (FEK) 
cells yielded Rasty's "prototype EIAV", and the propagation of Rasty's prototype 
EIAV by a serial passage in primary fetal donkey dermal (FDD) cell cultures 27 times 
yielded Rasty's "FDD-adapted EIAV" (Rasty et al., 1990; Schiltz et al., 1992; Cook et 
al., 1995). This prototype EIAV establishes a persistent, noncytopathic infection in 
cultured FEK cells. In cultured FDD cells, this virus causes a cytopathic infection 
characterized by rounding and detachment of infected cells 20 to 22 days 
postinfection. The FDD-adapted EIAV produced the same CPE only 10 to 12 days 
postinfection in cultured FDD cells (Rasty et al., 1990).
1.1.3.5. Cellular Transcription Factors Determined to Bind to EIAV LTR
Transcription factor binding studies for EIAV LTRs previously showed that a 
maximum of five different cellular transcription factors (MDBP, PEA2, PU. 1, API, 
and Oct-1) can recognize their own specific site(s) in the LTRs (Carvalho and Derse, 
1993a; Carvalho and Derse, 1993b; Carvalho et al., 1993; Maury, 1994). Before 
reviewing the EIAV LTR, some background of MDBP, PEA2, PUT, and API, the 
relatively important transcription factors in EIAV LTR-directed transcription, is first 
described.
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(1.) MDBP
Methylated DNA-binding grotein (MDBP)/enhancer binding factor to polyoma 
element C (EF-C)/factor binding to region EP of hepatitis B virus enhancer (EP)/site 
Ill-binding protein/myc mtron factor (MIF)/regulatory factor binding to X box (RF-X) 
(NF-X) (Huang et al., 1984; Ostapchuk et al., 1986; Ben-Levy et al., 1989; Ghazal et 
al., 1987; Zajac-Kaye et al., 1988; Reith et al., 1989) is a ubiquitous mammalian 
protein (Supakar et al., 1988) composed of homodimers or heterodimers of 
polypeptides RFX1, RFX2, RFX3, and RFX4, which are more distantly related to a 
protein necessary for expression of major histocompatibility complex class II genes 
(Zhang et al., 1993; Zhang et al., 1995). MDBP was first isolated on the basis of its 
preferential binding to some of its recognition sites when they are methylated at their 
CpG dinucleotides (Huang et al., 1984), but more recent evidence indicates that 
MDBP does not necessarily require methylated CpG for its binding (Zhang et al., 
1989). MDBP binds to its partially symmetrical MDBP consensus sequence 
(RTYRYYAYRGYRAY, where Y = thymine or 5-methylcytosine; R = A or G; Y = C 
or T: Zhang et al., 1989; Locker, 1993). Responsiveness of MDBP to 
12-0-tetradecanoylphorbol-13-acetate (TP A) which is an activator of protein kinase C 
(PKC) is not known, but gel shift results of an MDBP oligonucleotide using nuclear 
extracts prepared from human epithelial carcinoma (HeLa) cells treated with TP A for 
up to three hours showed uniformly strong binding activity, suggesting that either 
MDBP does not respond to TPA or untreated HeLa cells already contain an equally 
high level of MDBP activity (Carvalho and Derse, 1993a). MDBP has been implicated
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in both positive (Ostapchuck et al., 1989) and negative (Zhang et al., 1990; Asiedu et 
al., 1994) transcriptional regulation. Ostapchuck et al. (1989) found that mutations in 
the MDBP site of the human hepatitis B virus enhancer reduce enhancer activity about 
10-fold in transient gene expression assays.
(2.) PEA2
PEA2 (polyoma enhancer A binding factor 2/polyomavirus enhancer A binding 
protein 2)/PEBP2 (polyomavirus enhancer binding protein 2) (Piette and Yaniv, 
1987/Martin et al., 1988; Ogawa et al., 1993a) was originally identified as the factor 
binding to the early proximal part of the a  (A) domain of polyoma virus enhancer. 
PEA2 is a heterodimer formed by two subunits, a  (30-35 kDa) that has DNA binding 
activity, and 3 (20-25 kDa) that increases the affinity of the a  subunit to DNA 
without binding to DNA by itself (Kamachi et al., 1990; Ogawa et a l, 1993a). While 
the 3 subunit is expressed ubiquitously (Ogawa et al., 1993a; Ogawa et al., 1993b), 
the a  subunit is expressed in a highly cell-type specific manner: it is known that the a  
subunit is expressed at high levels in T cells but at a very low level in B cells (Ogawa 
et al., 1993 a; Zent et al., 1996). Expression of a  subunit in other cell types has not 
been characterized. It is not known whether PEA2 is TPA-inducible or not in any cell 
type. However, Satake et al. (1989) reported that TP A treatment induces more 
PEA2-binding activity in mouse whole embryonic (NIH 3T3) cells, although Jones, N. 
C. et al. (1988) described that PEA2 is not TP A-inducible. PEA2 binds the consensus 
sequence, 5' R/TACCRCA (R, purine) (Kamachi et al., 1990; Ogawa et a l, 1993a), 
and functions as a transcriptional activator (Ogawa et a l, 1993a).
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(3.) API
The ubiquitous and TP A-inducible transcription factor API, also designated 
AP-1 (activator protein-1), consists of a mixture of homodimers (Gabuzda et al.,
1989; Halazonetis et al., 1988; Trejo et al., 1994) of Jun family members (c-Jun,
JunB, and JunD) and heterodimers between Jun family members and Fos family 
members (c-Fos, FosB, Fra-1, and Fra-2). They dimerize through a leucine zipper 
motif. API binds the palindromic consensus sequence, 5' TGACTCA 3', referred to as 
the TP A response element (TRE). TPA-stimuIation of API stimulates transcription 
from a number of viral and cellular promoters. API can also repress gene activity 
through negative protein-protein interactions with other transcription factors (Curran, 
T. and P. K. Vogt, 1992; Karin, M , 1991; Curran, T., 1991; Angel and Karin, 1991; 
Sassone-Corsi, P., 1994). Canonne-Hergaux et al. (1995) recently reported that the 
two putative API sites (5' TGACCCC 3' and 5' TGAGCCA 3') in the regions of LTR 
(nts -352 to -324, and nts -306 to -285) of lymphotropic HIV-1 isolates are not 
functional, but that the API sequence (5‘ TGAGCCA 3') in the region of LTR (nts 
-247 to -222) of neurotropic HTV-1 isolates is functional in their host cells. This 
illustrates the differences in transcriptional utilization of various API sites, depending 
on both the cell type and the viral strain.
(4.) PU.l
PU. 1/spleen focus forming virus (SFFV) proviral integration site-1 binding 
protein (Spi-IVSFFV proviral integration site-I binding protein (Sfpi-l)/nuclear factor 
binding to JB element (NF-JB)/nuclear factor 0A (NF0A) (Klemsz et al., 1990;
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Moreau-Gachelin et al., 1988; Paul et al., 1991; Shin and Koshland, 1993; Buras et 
al., 1995) is a member of Ets family. Ets proteins bind as monomers to target DNA 
sequences, and they regulate transcription (Janknecht and Nordheim, 1993). PU. 1 
was characterized as a protein which could bind to an oligonucleotide containing a 
purine-rich core consensus sequence called the PU box (5' GAGGAA 3') that is a part 
of a full consensus sequence (5' AGAGGAACT 3': Faisst and Meyer, 1992). PU. 1 
was shown to be expressed specifically in hematopoietic tissues, particularly in the 
monocytes/macrophages and B lymphocytes (Klemsz et al., 1990; Galson et al., 1993; 
Scott et al., 1994). Numerous putative PU.l target genes have been identified in these 
cell types. Thus, PU. 1 has been suggested to control the differentiation of monocytes 
and B lymphocytes. It has been demonstrated that purine-rich sequences with the PU 
box can function, as a typical enhancer, in either orientation and either upstream or 
downstream of a reporter gene promoter (Klemsz et al., 1990). PU. 1 can be 
stimulated by TPA (Carvalho and Derse, 1993a; Kominato et al., 1995).
1.1.3.6. The EIAV LTR
The c/s-acting regulatory elements that control lentiviral gene expression 
normally reside in the LTR of the virus, particularly within the U3 region (Nabel,
1993). The U3 region of lentiviral LTR contains the promoter and enhancer elements 
that control viral gene transcription. The enhancer elements are bound by cellular 
transcription factors to activate basal transcription of the viral genome. All viral 
mRNA transcripts initiate transcription at the RNA cap site (nt +1), the first nt of the 
R region in the 5' LTR and terminate in the 3' LTR at the polyadenylation signal.
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(Clements and Payne, 1994). The U3 region of the lentiviral LTR has a high degree of 
heterogeneity, and particularly in the case of EIAV U3 region there is a hypervariable 
region between nt -50 and -80 from the transcription initiation site of the prototype 
EIAV LTR (Derse et al., 1987; Derse et al., 1993).
Prototype EIAV LTR (designated PLTR in this dissertation) is described here 
as a representative EIAV LTR. This small EIAV LTR has been examined in most 
detail with respect to transcription factor binding and promoter function (Carvalho and 
Derse, 1993a). The 302-bp long PLTR consists of 189-bp U3, 77-bp R, and 36-bp U5 
regions (Derse et al., 1987). The R region contains the EIAV TAR element localized 
to +1 to +25 (see 1.1.3.2). The U3 region of the EIAV LTRs examined thus far 
contains a TATA box located between around -23 and -29.
(1.) Negative Regulatory Element (NRE) Region 
Chloramphenicol acetyltransferase (CAT) assay for progressive 5' deletions of 
the prototype LTR localized an NRE between -76 and - 111 whose deletion increased 
the basal promoter activity nearly 30-fold in an uninduced feline embryo fibroblast cell 
line (FEA), but this increase was not evident in an uninduced canine osteosarcoma cell 
line (D17) (Dorn and Derse, 1988). In addition, the same deletion decreased 
Tat-transactivated promoter activity to approximately 60% and 40% of wild-type 
levels in uninduced D17 and HeLa cells, respectively (Carvalho and Derse, 1993a).
On the other hand, deletion from nt -50 to the 5' end (-207) in another EIAV LTR 
generated a 5-fold increase of basal promoter activity in an uninduced canine fetal 
thymus fibroblastic cell line (C£2Th), but this NRE region from nt -50 to -207 acted as
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an enhancer in the same ceil line when inserted upstream of an enhancerless 
noncognate simian virus 40 (SV40) promoter (Sherman et al., 1989). These 
inconsistent results suggest that there are cell type-specific transcription factors which 
are capable of interacting with the NREs. Thus, it is clear that the NRE results are 
critically dependent on the cells used and may not be totally relevant to the in vivo 
situation (Montelaro et al., 1993).
(2.) MDBP Region (nts -79 to -111 of PLTR)
General background for MDBP was described above [1.1.3.5.(1.)]. EIAV 
MDBP site was first identified by computer search (Ben-Levy et al., 1989). It has 
been previously shown only by gel shift assays to bind to partially purified human 
placental MDBP in a DNA methylation-independent fashion (Zhang et al., 1989), or 
to crude nuclear extracts from uninduced D17, human B (Raji), and human monocyte 
(THP-1) cells (Carvalho and Derse, 1993a). The function of EIAV MDBP essentially 
has not been studied.
(3.) PEA2 Region (nts -60 to -80 of PLTR)
Carvalho and Derse (1993a) performed detailed studies on EIAV PEA2 sites. 
They identified 3 putative PEA2 sites in EIAV PLTR by DNase I footprinting using 
heparin-enriched nuclear extract of uninduced D17 cells. A tandem repeat of putative 
PEA2 sequences (51 AACCGCA 3') was localized in the region between nt -60 and 
-80, and the third putative PEA2 sequence (5' GACCGCA 3') was localized in the 
region between nt +7 and +24. Gel shift assay results showed that the putative PEA2 
sites interact with nuclear extracts from various cell types and form specific
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complexes, and that there is a very different level of binding activity for the putative 
EIAV PEA2 sites among different cell types (Carvalho and Derse, 1993a). The 
binding activity has been shown to be high in D17, equine 6288 (equine fibroblast), 
and THP-1 cells, but very low in Raji and HeLa cells (Carvalho and Derse, 1993 a).
Transient gene expression assays of Tat-transactivated promoter activity using 
various PEA2-site mutants showed that the tandem-repeated PEA2 sites are 
positively-acting (simultaneous mutation of these two sites reduced Tat-transactivated 
promoter activity to 58% of its wild-type level), dispensable individually, and 
orientation-independent transcriptional regulatory elements in uninduced D17 cells 
(Carvalho and Derse, 1993a). In uninduced THP-1 cells, the simultaneous mutation of 
the tandem-repeated PEA2 sites reduced Tat-transactivated promoter activity to about 
50% of wild type level (Carvalho and Derse, 1993b). The function of the third 
putative PEA2 site has not been studied.
The second putative PEA2 site (i.e., the downstream one of the 
tandem-repeated PEA2 sites) corresponds to the hypervariable region of variant EIAV 
LTRs. The hypervariable region is about 10 to 40 bp in length, and it is variable in 
organization of transcriptional elements (Carvalho et al., 1993). The functional 
comparison between variant LTRs must be complex and has not been systematically 
studied.
(4.) API Region (nts -45 to -60 of PLTR)
The putative API site of PLTR (5' TGACGCG 3' from nt -50 to -57) has not 
been previously studied in detail. It has a sequence similarity to c-fos API site (5’
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TGACGCA 3') (Fisch et al., 1989) and has been shown only by gel shift assays to 
form specific complexes with uninduced D17 and TPA-induced HeLa cell nuclear 
extracts (Carvalho and Derse, 1993a). However, the complex formation was not 
effectively competed by oligonucleotide containing the consensus sequence (Carvalho 
and Derse, 1993a). This suggests that the putative EIAV API site binds different API 
heterodimers compared with the consensus API site. Carvalho and Derse (1993a) 
showed that the EIAV API site is, in addition to PU. 1 site, important for response to 
TP A. Mutation of the API site reduced the Tat-transactivated promoter activity to 
50%, 14%, and 5% of wild-type levels in uninduced THP-1, D17, and HeLa cells, 
respectively (Carvalho and Derse, 1993b; Carvalho and Derse, 1993a), suggesting that 
the API site plays a critical role in EIAV gene expression.
(S.) Octamer Region (Core: nts -43 to -SO of PLTR)
The putative octamer site of PLTR is located in a DNase I footprinted region 
from nt -34 to -50 using a heparin-enriched nuclear extract from uninduced D17 cells 
(Carvalho and Derse, 1993a). This putative octamer site overlaps with the API and 
PU. 1 sites. This octamer site has been shown by gel shift assays using uninduced D17 
nuclear extracts to form a specific complex if the PU. 1 site is mutated or if PU. 1 
binding activity is competed away using PU. 1 oligonucleotides (Carvalho and Derse, 
1993a). Thus, the octamer site was postulated to bind an octamer binding protein 
when it is vacated. The function of the octamer site remains to be determined.
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(6.) PU.l Region (nts -30 to -45 of PLTR)
EIAV PU. 1 site has been studied in detail by Carvalho and Derse (1993a; 
1993b) and by Maury (1994). PLTR PU. 1 site is located in the DNase I footprinted 
region from nt -34 to -50 (Carvalho and Derse, 1993a). Two-bp changes in the PU. 1 
core sequence reduced the Tat-transactivated promoter activity to 12% to 20% of 
wild-type levels in uninduced D17 cells, while the promoter activity was completely 
abolished in uninduced HeLa and THP-1 cells, suggesting that the PU.l motif is 
essential for promoter activity (Carvalho and Derse, 1993a; Carvalho and Derse, 
1993b). In addition, Carvalho and Derse (1993a) showed that the PU.l site is the 
primary determinant of TP A responsiveness of EIAV LTR.
By gel shift assays with (supershifting) and without antisera against whole 
PU.l protein and peptide derived from non-DNA binding domain of PU.l, 
respectively, Carvalho and Derse (1993b) showed that the EIAV PU.l site specifically 
binds PU. 1 protein. They showed this by (i) oligonucleotide containing the PU. 1 site 
(nts -34 to -45) forms a complex with nuclear extracts from human monocytes 
(THP-1, U937), human B cells (Raji), and HeLa cells [HeLa(+PU.l)] transfected with 
a PU. 1 expression plasmid; (ii) the oligonucleotide was shown by competition 
experiments to form a specific complex with nuclear extracts from THP-1 and 
HeLa(+PU.l) cells; (iii) the oligonucleotide could be supershifted when the antiserum 
against the peptide was incubated with nuclear extracts from THP-1, U937, and 
HeLa(+PU. 1) cells prior to incubation with the oligonucleotide; (iv) as expected, the 
antiserum against whole PU.l protein interfered the formation of PU.l-specific
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complexes. In uninduced HeLa cells PU.l protein expression resulted in a 10-fold 
increase in Tat-transactivated promoter activity, and in uninduced THP-1 cells 
mutation of PU. 1 site abolished the promoter activity but mutation of either PEA2 or 
API site resulted in only 50% decrease in the promoter activity. This suggests that the 
PU.l site is the major determinant of the Tat-transactivated promoter activity in 
uninduced monocytes. Cooperation among PU.l, PEA2, and API sites is required, 
however, for maximal promoter activity (Carvalho and Derse, 1993b).
The definitive study of EIAV PU.l was performed by Maury (1994) who used 
primary horse monocyte cultures and LTR isolates derived from an EIAV field isolate 
(Th-1) which is heterogeneous in genetic nature (Carpenter et al., 1991). The LTR 
isolates were obtained as follows: horse monocytes were infected with the Th-1 
isolate, held as nonadherent cells for 4 days, and then allowed to adhere to culture 
flasks for an additional 6 days. Thus, the infected monocytes could mature into 
adherent macrophages; from these infected macrophages, mRNA was extracted and 
used for synthesis of complementary DNA (cDNA); then, amplification of the cDNA 
yielded two full-length LTR isolates (called Mac 1 and Mac 2). The enhancer 
sequence encompassing the region from nt 111 to 185 of Mac 1 has the enhancer 
organization of 5' PEA2-PU. 1-PU. 1-APl-like-PU. 13'. Except for a single base 
deletion between the API-like sequence and the most-downstream PU. 1 site, the 
enhancer sequence of Mac 1 is identical to that of Th-1.131 (Carpenter etal., 1991) 
which was derived directly by polymerase chain reaction (PCR) from the in vivo Th-1 
stock. The enhancer sequence of Mac 2, compared with that of the Mac 1, has a 13-nt
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deletion in the middle PU. 1, and a single base deletion with a 4-nt substitution in the 
API-like sequence, and thus all the functional enhancer elements of Mac 2 are 
included in the Mac 1 enhancer region (Maury, 1994).
Gel shift assays (Maury, 1994) showed that nuclear extracts from the adherent 
macrophages form specific DNA-protein complexes with the three PU.l sites of Mac 
1, but no complexes with the API-like and PEA2 sites of Mac 1: it is understandable 
that the API-like sequence does not form a complex with the nuclear extracts because 
the API-like sequence (5' TGACGTG 3') is not a good API sequence, and it has not 
been reported as API sequence; the PEA2 site of Mac 1 has the same binding core 
sequence and the same three-nucleotide flanking sequences with the most upstream 
PEA2 site of PLTR, and thus, no complex formation of Mac 1 PEA2 site with the 
adherent horse macrophages suggests that the adherent horse macrophages do not 
express PEA2 binding protein. The binding specificity of the three PU. 1 sites to PU. 1 
protein was proven by supershifted bands formed when antisera against PU.l, but not 
antibodies against other members of the Ets family [Etsl and 2, and polyomavirus 
enhancer A binding protein 3 (PEA3)], were employed in the gel shift assays (Maury,
1994).
The function of the PU. 1 sites was studied by CAT assays (Maury, 1994) using 
a PU. 1 mutant construct containing the simultaneous mutation of the three PU. 1 sites 
and Cf2Th cells and the adherent horse macrophages without TPA treatment. 
Mutagenesis of the PU.l motifs did not affect either the basal or Tat-transactivated 
promoter activity in uninduced Cf2Th cells. However, in the uninduced adherent
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macrophages, the basal promoter activity was reduced to 76% of the wild-type level 
by the simultaneous mutation of the three PU. 1 sites, whereas the Tat-transactivated 
promoter activity was reduced eighteenfold by the same mutation. This suggests that 
PU. 1 bound to its cognate sites interacts with EIAV Tat-TAR complex presumably 
indirectly via cellular protein(s) inducible during maturation of monocyte into 
macrophage to enhance promoter activity of EIAV LTR. Thus, the PU. 1 sites are 
important for Tat-transactivated promoter activity in macrophages. In summary, it 
appears that provirus transcription in horse macrophages is governed primarily 
through the expression and subsequent binding of PU. 1 protein to the PU. 1 sites in the 
EIAV LTRs.
1.2. Research Objectives
The overall goal of the research presented in this dissertation was to 
characterize the U3 region of EIAV LTRs physically and functionally as a gene 
expression study of EIAV. The specific goals were as follows: (1) localization of the 
transcriptional elements in the entire U3 region of the 4 EIAV LTRs (P, A, V470, and 
V3291 LTRs) by DNase I footprinting and gel shift assays using TPA-induced and 
uninduced U937 nuclear extracts and purified c-Jun/APl; (2) examination of the 
contribution of each transcriptional element of the EIAV ALTR to both TPA-induced 
and uninduced basal promoter activities by using transient gene expression luciferase 
assays of the mutants of each element; (3) examination of TPA-responsiveness of the 
transcriptional elements; (4) analysis of the hypervariable region in the U3 region of 
the 4 EIAV LTRs.




A list of reagents employed in this study and their sources of supply is 
enumerated below. Fetal calf serum (FCS) was purchased either via Louisiana State 
University School of Veterinary Medicine (LSU SVM), Baton Rouge, LA originally 
obtained from Intergen Co. (Purchase, NY) or from Atlanta Biologicals, Inc. 
(Norcross, GA). Roswell Park Memorial Institute (RPMI) medium and Eagle's 
minimum essential medium (MEM) were purchased via LSU SVM, or prepared using 
powdered media from Sigma Chemical Co. (St. Louis, MO). Gentamicin was 
obtained from Sigma or Gibco BRL (Div. of Life Technologies Inc., Gaithersburg, 
MD). 12-O-tetradecanoylphorbol-13 -acetate (TP A) and phenylmethylsulfonylfluoride 
(PMSF) were obtained from Sigma. Purified human homodimeric c-Jun protein was 
purchased from Promega Corp. (Madison, WI). T4 polynucleotide kinase was 
obtained from New England Biolabs (Beverly, MA). Calf intestinal alkaline 
phosphatase (CIAP) was obtained from Boehringer Mannheim Biochemicals 
(Indianapolis, IN). Deoxyribonuclease I (DNase I) was obtained from Gibco BRL. 
Bovine serum albumin (BSA), poly(dI-dC).poly(dI-dC), and sonicated salmon sperm 
DNA (SS DNA) were purchased from Pharmacia Biotech Inc. (Piscataway, NJ). 
Oligonucleotides were custom-synthesized by the GeneLab at LSU SVM using a 
Cruachem PS250 DNA synthesizer (Cruachem, Sterling, VA). [y-32P]adenosine 
5'-triphosphate (ATP) was purchased from ICN Biomedicals Inc. (Costa Mesa, CA).
44
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Maxam-Gilbert DNA sequencing system was obtained from DuPont Co. (Boston, 
MA). Plasmids pSV/p-Galactosidase Control Vector, pGL2-Enhancer Vector and 
pGL2-Control Vector were purchased from Promega.
2.2. Cell Culture
U937 cells (Sundstrom and Nillson, 1976) were kindly provided by Dr. J. E. 
Clements of the John Hopkins University. These cells were maintained in RPMI-1640 
medium supplemented with 10% FCS and 50 pg/ml gentamicin at 37° C with 5% CO-,. 
For induction, TP A was added at a final concentration of 160 nM (Anderson and 
Clements, 1991; Gabuzda et al., 1989) at 4 hours before harvesting for preparation of 
TPA-induced nuclear extracts or 30 nM (Pahl et al., 1991) at 8 hours prior to 
harvesting for luciferase assays. Primary cultures of fetal donkey dermal (FDD) cells 
were obtained from Dr. C. J. Issel (formerly of the Department of Veterinary Science, 
LSU, Baton Rouge, LA and currently with the Department of Veterinary Science, 
University of Kentucky, Lexington, KY). FDD cells were maintained in Eagle's MEM 
supplemented with 10% FCS, 50 |ig /ml gentamicin at 37°C with 5% CO,.
2.3. Preparation of Nuclear Extracts
Nuclear extracts were prepared on the same days both from uninduced U937 
cells and from U937 cells induced for 4 hours with TPA (see 2.2.; Rovera et al., 1979) 
by the procedure of Dignam et a/.(1983). Protein concentrations were determined by 
bicinchoninic acid (BCA) protein assay using BSA as the standard (Pierce Chemical 
Co., Rockford, 111.).
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2.4. Oligonucleotide Probes for Gel Shift and Footprinting Assays
N F-kB consensus oligonucleotide, which contains the mouse kB  sequence 
element (Sen and Baltimore, 1986), was purchased from Promega and used as the 
competitor without further purification. API consensus oligonucleotide Visna API 
(Table 1), derived from the visna virus LTR (Shih et al., 1992), was a gift from Dr. J. 
E. Clements. All EIAV LTR-derived oligonucleotides were synthesized using the 
Cruachem PS250 DNA synthesizer at LSU SVM, and purified by gel electrophoresis 
as described (Sambrook et al., 1989). Purified complementary strands were mixed in 
equal molar amounts in oligonucleotide annealing buffer (70 mM Tris-Cl, pH 7.6, 100 
mM KC1, and 10 mM MgCU), heated to 98° C and allowed to cool slowly to room 
temperature overnight to permit the formation of a duplex DNA. Nucleotide
sequences of all the oligonucleotide probes used in this research are shown in Table 1 
Table 1. Sequences of oligonucleotides used for gel shift and footprinting assays
Name (Other Name)1 Sequence1* Length
NF-kB 5'-AGTTGAGGGGACTTTCCCAGGC-3' 22 bpc
Visna API (Vis-59/-41) 5 ’ -ATGCTTGAGTCATAACCGC-3' 19 bp
PLTR API (P-45/-63) 5'-GCATTTGTGACGCGTTAAC-3' 19 bp
ALTR APIA (A-40/-60) 5'-TTGTGACGCATTTAACTTCCT-3' 21 bp
ALTR APlAm (A-44/-66m) 5'-CCACATTTGTTTTGCATTTAACT-3' 23 bp
ALTR AP1B (A-67/-86) 5'-CCGCATTTGTGACGCGAGTT-3' 20 bp
ALTR APlBm (A-63/-86m) 5'-CCGCATTTGTTTTGCGAGTTCCAC-3' 24 bp
ALTR AP1C (A-108/-126) 5'-AAGGACTAGCTCATGTTGC-3' 19 bp
ALTR AP1D (A-138/-158) 5 1 -TTGCTGATGCTCTCATAACCT-3 ' 21 bp
ALTR AP1E (p-139/-163) 5 ' - AAATGATTATAAGAGTAAAAAGAAA- 3 ' 25 bp
ALTR AP1F (A-185/-209) 5'-GTGGGGTTTTTATGAGGGGTTTTAT-3' 25 bp
* "P" and "A" represent PLTR and ALTR, respectively, and "m" represents mutation. 
b Only upper strands are shown with putative API core sequences which are 
bold-faced, and with mutated nucleotides underlined. 
c Base pair.
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2.5. 290-bp Prototype EIAV LTR Fragment for Gel Shift Assay
The fragment was prepared as follows. Plasmid pPLTR (see 2.6.) was purified
by precipitation with polyethylene glycol (Sambrook, et al., 1989) and digested with 
Hind HI and EcoK I. The resulting 432-bp Hind IH-iscoR I fragment containing the 
entire PLTR was isolated by low melting point agarose gel electrophoresis followed by 
extraction of the fragment from gel slices using the following procedure. Excised gel 
slices were melted with an equal volume of a buffer solution [0.4 M NaCl, 20 mM 
Tris-Cl, pH 8.0, 2 mM ethylenediaminetetraacetic acid (EDTA)] at 67° to 70° C for 5 
minutes. The melted gel solution was extracted sequentially with an equal volume of 
buffered phenol (65° C), chloroform, butanol, and chloroform. DNA was precipitated 
with ethanol, and dissolved in water. The 432-bp was then digested with Mnl I and 
Sau3A I, and the resulting 290-bp fragment was purified by using the same procedure 
as described above. Finally, the fragment was dephosphorylated using CLAP 
(Boehringer Manheim).
2.6. Plasmids Used to Prepare Probes for Gel Shift and DNase I Footprinting 
Assays
The plasmid pPLTR which contains the 3' LTR sequence of the prototype 
EIAV (see 1.1.3.4.) was kindly provided by Dr. K. E. Rushlow (formerly of the 
Department of Biochemistry, LSU and currently with Paravax Inc., Fort Collins, 
Colorado). This plasmid contains an insert of 383 bp Dra l-Ssp I fragment (Rushlow 
et al., 1986) at Him  II site of pUC13 in the same direction with lac Z gene 
transcription. The insert contains, in addition to the entire LTR sequence, at the 5' end 
a 43-bp segment derived from the 3' end of the envelope gene and the polypurine tract 
and at the 3' end a 21-bp equine cellular DNA.
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Plasmids containing variant LTR sequences (pV470LTR and pV3291LTR) 
were also provided by Dr. K. E. Rushlow. These plasmids contain in a pUC13 
backbone the variant 3' LTRs of the cDNAs 470 and 3291, respectively. A brief 
description on the synthesis of the cDNAs and the construction of the recombinant 
plasmids is given below. The cDNAs 470 and 3291 were prepared using viral RNAs 
purified from virus isolates P3.2.1 and P3.2.5, respectively, recovered during two 
different febrile episodes from the same pony infected with the prototype EIAV. The 
cDNAs were dC-tailed and cloned into Pst I-cut, dG-tailed pUC9 (Payne et al., 1987). 
Then, Dra 1-EcoK I fragments from the recombinant pUC9 plasmids were ligated to 
the Him  II-EcoR I large fragment of pUC13. The resulting variant EIAV plasmids 
were, by sequencing, found to be intact in the U3 region but deleted from the end of 
the terminal redundancy (R) region.
The plasmid pALTR (also termed pAFDD3/Blue) which is the AFDD LTR 
clone 3 in pBluescript was kindly provided by C. R  Madden in Dr. D. S. Shih's 
laboratory at LSU. This plasmid was constructed as follows. FDD cell-adapted 
(AFDD) EIAV which is identical to Rasty's FDD-adapted EIAV (see 1.1.3.4.) was 
used to infect FDD cultures. Then, to obtain proviral DNA, genomic DNA was 
prepared from the infected FDD cultures by the procedure of Strauss (1990) with 
some modifications as follows. The infected FDD cell cultures were washed with 
phosphate-buffered saline (PBS), and harvested 6 days post-infection with PBS/10 
mM EDTA. Cells were resuspended in lysis buffer [10 mM Tris-Cl, pH 8.0, 100 mM 
NaCl, 25 mM EDTA, 0.1 mg/ml proteinase K, 0.5% sodium dodecyl sulfate (SDS)],
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and incubated at 55° C overnight. The lysate was subjected to phenol and 
phenol/chloroform extractions, followed by ethanol precipitation and centrifugation. 
The pellet was resuspended in 50 mM tris(hydroxymethyl)aminomethane-Cl (Tris-Cl) 
(pH 8.0), 10 mM MgC^, 50 mM NaCl, and 20 pg/ml ribonuclease (RNase) A, and 
incubated at 37° C for one hour. The solution was extracted with phenol/chloroform, 
and DNA was precipitated with ethanol sequentially in the presence of 2.5 M 
ammonium acetate. The pellet was air-dried and resuspended in TE (pH 7.6) (see 
APPENDIX 1) at 50° C overnight and quantitated. Next, from the isolated cellular 
DNA, AFDD LTR was amplified by PCR. Amplication of the 3' LTR was performed 
using the primer pair, ->ALTR5'
(5 '-ATTATGAAGCTTATGTATCAATGCCTCA-3', Hind m  site indicated in bold) 
and <-ALTR3' (5-ATAATCCAGCTGTAGGATCTCGAACA-3', Pvu II site 
indicated in bold). The reaction was performed in a solution [20 mM Tris-Cl, 10 mM 
KC1, 10 mM (NHJ^SO^ 0.1% Triton X-100, 6 mM MgSO* 200 pM 
deoxyribonucleoside triphosphates (dNTPs), 2 pM primers each, 0.5 pg the cellular 
DNA as template, and 2 units Vent (exo‘) DNA polymerase (New England Biolabs, 
Beverly, MA)] at 94° C for 1 minute, and 60° C for 30 seconds for 35 cycles. The 
PCR product was digested with Hind IE and Pvu II and ligated into Hind TWEcoR. 
V-digested pBluescript IIKS (+) (Stratagene, La Jolla, CA) to form pAFDD/Blue 
construct. Clones were screened by a-complementation and verified to be intact in the 
entire LTR region by sequence analysis using a sequencing kit (United States 
Biochemical, Cleveland, OH) as recommended by the manufacturer.
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For better resolution in footprinting gels of the 3' half of the U3 region, 
mutant plasmids containing 5' deletion up to the Alu I site in the LTR, pPLTR(-96), 
pV470(-l 16), pV3291(-125), and pALTR(-l 17) were constructed from the parental 
plasmids, pPLTR, pV470, pV3291, and pALTR, respectively. The procedures for 
constructing the mutant plasmids are as follows. The parental plasmids were digested 
with Hind EH and EcoR I, and the fragments containing LTR were gel-purified. These 
fragments were digested with Alu I and used without further isolation in ligation 
reaction with a pUC 19 backbone. The backbone was prepared by digesting pUC 19 
with Sma I and EcoR I, followed by dephosphorylating the digested fragments with 
CIAP and gel-purifying the large Sma 1-EcoR I fragment. Clones were screened by 
a-complementation and verified by restriction digestions.
The plasmid pyiS5’(-140) [also termed pVES-LTR(5'-140)-CAT] which 
contains visna LTR was kindly provided by Dr. J. E. Clements. This plasmid has been 
described previously (Hess, et al., 1989). In this plasmid, the visna virus LTR was 
deleted from its 5' end to nt -139, however, its API sites were intact and the CAT 
activities were similar to those of its wild-type plasmid in various cell-lines including 
sheep macrophages (Hess, et al., 1989).
All plasmid DNAs were prepared by standard procedures including alkaline 
lysis of plasmid-harboring bacteria and subjected to two cycles of centrifugation 
through CsCl-ethidium bromide (EtBr) density gradients in Ti or NVTi rotor 
(Beckman Instruments, Fullerton, CA). After ultracentrifiigation, the EtBr and CsCl 
were removed by repeated extractions with water-saturated butanol followed by
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ethanol precipitation (Sambrook, et al., 1989). The DNAs were dissolved in water 
and stored at -20° C or below.
2.7. Full-length EIAV LTR CAT Plasmids for the Construction of Full-length 
EIAV LTR Luciferase Reporter Vectors
Construction of the pPLTRCAT vector containing the 5' LTR of EIAV lambda 
clone 12, also termed pEI-lcat, pLTRCAT, or pLTRcat, has been previously 
described (Derse et al., 1987; Rasty et al., 1990; Schiltz et al., 1992). This plasmid 
was constructed by inserting, into pSVOCAT (Gorman et al., 1982), a 478-bp 
fragment excised from lambda clone 12. The fragment consists, in the 5' to 3' 
direction, of a 175-bp cellular DNA sequence, the entire 5' LTR, and one additinal bp 
(Derse et al., 1987).
Variant EIAV LTR (VLTR) CAT plasmids, pV470LTRCAT and 
pV3291LTRCAT, were constructed by Dr. K. E. Rushlow as follows. Firstly, 
pV470LTR and pV3291LTR (see 2.6.) were digested with Hind HI and Mlu I, and 
the Hind lll-Mlu I fragments containing the VLTR sequences from the 5' end to nt -50 
were gel-purified. Secondly, pPLTRCAT was digested with Hind HI and BamH I, 
and the Hind JII-BamH I fragment containing the ampicillin resistance gene was 
gel-purified. Thirdly, pPLTRCAT was digested with Mlu I and BamH I, and the Mlu 
1-BamH I fragment containing the PLTR sequence from nt -53 to the 3' end and CAT 
gene was gel-purified. Finally, the three fragments, Hind YH-Mlu I, Hind VB-BamH I, 
Mlu 1-BamH I were used in triple ligation reactions. Positive clones were screened by 
restriction digestions and verified by sequencing. The constructs produced contain
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
52
variant LTR U3 sequences upstream of the M m I site, which include the hypervariable 
region, with the remainder of the LTR being identical to the prototype sequence.
AFDD EIAV LTR CAT plasmid, pALTRCAT, was constructed by C. R. 
Madden as follows. First, pALTR (see 2.6.) was digested with Hind HI and Pvu II, 
and Hind III-Pvw n  fragment containing the entire ALTR was gel-purified. Next, 
pSVOCAT was also digested with Hind HI and Pvu II, and Hind TR-Pvu II large 
fragment was gel-purified. The two fragments were ligated to form pALTRACAT. 
Then, pALTRACAT was digested with Stu I and BamH I, and Stu 1-BamH I large 
fragment containing the ALTR sequences upstream of the Stu I site was gel-purified. 
Also, pPLTRCAT was digested with Stu I and BamH I, and Stu 1-BamH I small 
fragment containing the ALTR sequences downstream of the Stu I site and CAT gene 
was gel-purified. Finally, the two Stu 1-BamH I fragments were ligated to construct 
the pALTRCAT. Clones were screened by restriction digestions and verified by 
sequencing.
2.8. LTR Luciferase Reporter Vectors
The luciferase reporter vectors, which were kindly provided by C. R  Madden 
were constructed as follows. The full-length EIAV LTR CAT plasmids, pPLTRCAT, 
pV470LTRCAT, pV329lLTRCAT, and pALTRCAT, were digested with Hind HI, 
and the small fragments containing LTR were gel-purified and ligated into Hind ID-cut 
pGL2-Enhancer vector (Promega, Madison, WI) to generate full-length EIAV LTR 
luciferase plasmids, pPLTRLuc, pV470LTRLuc, pV3291LTRLuc, and pALTRLuc, 
respectively. Clones were screened for orientation of LTRs in the same direction with
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luciferase gene transcription by restriction enzyme analysis. Plasmid pVISLTRLuc 
was constructed as follows. The plasmid pVIS5'(-140) (see 2.6.) was digested with 
Kpn I and Hind HI, and the small fragment containing the visna virus LTR sequence 
was gel-purified and ligated into large Kpn l-Hind HI fragment of pGL2-Enhancer 
Vector to form a visna virus LTR luciferase plasmid, pVISLTRLuc. Clones were 
screened by restriction digestion.
DNAs of these LTR luciferase plasmids were prepared by standard procedures 
including alkaline lysis of plasmid-harboring bacteria and subjected to two cycles of 
centrifugation through CsCl-EtBr density gradients in VTi rotor (Beckman). After 
ultracentrifugation, the EtBr and CsCl were removed by repeated extractions with 
water-saturated butanol followed by ethanol precipitation (Sambrook, et al., 1989). 
The DNAs were dissolved in water and stored at 4°C.
2.9. Deletion Mutants of the EIAV ALTR Luciferase Plasmid (pALTRLuc)
Deletion mutants, which were also provided by C. R  Madden, were 
constructed from the pALTR (see 2.6.), using a primer-directed method. In brief, the 
procedure used a pair of primers which flanked the region to be deleted to amplify the 
remainder of the LTR and the entire vector to produce a linear molecule, which was 
subsequently ligated intramolecularly simply by using T4 DNA ligase and propagated 
within Escherichia coli DH5a. The amplification reactions (100 |il) were performed 
in 20 mM Tris-Cl (pH 8.8), 10 mM KC1, 10 mM (NH^SO* 0.1% Triton X-100, 6 
mM MgS04, 200 |iM of each dNTP, 1-2 |iM of each primer, 2 ng of template DNA 
(pALTR), and 2 units of Vent DNA polymerase with proofreading exonuclease
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activity (New England Biolabs) at 94° C 2 minutes, 62° C 1 minute, and 72° C 3 
minutes for 25 cycles. The amplified products were screened by sequencing, and 
correct mutant LTR sequences were excised from pALTR with Kpn I and Sac I, and 
inserted into the pGL2-Enhancer Vector (Promega) similarly digested. The primer 
pairs used and their deletion constructs are described in Table 2. Plasmid DNAs of the 
deletion mutants were prepared and stored as described in section 2.8.
Table 2. Deletion mutants of pALTRLuc
Deletion Construct Primer Pair
pD(-31/-46)Luc
—»ALTRP 1: 5 ' -GTATATAAGTGCTTGTATTCTGA- 3 ' 
<—ALTRP2: 5 ' -TAAATGCGTCACAAATGTGGAA-3 '
pD( — 43/—57)Luc
—>ALTRP3: 5'-CCTGTTTTTACAGTATATAAGTG-3' 
<—ALTRP 4 : 5 1-CAAATGTGGAACTCGCGTCA-3'
pD(-61/-77)Luc
—»ALTRP 5 : 5'-TTGTGACGCATTTAACTTCCT-3' 
<—ALTRP 6: 5 1-CAAATGCGGTTATTGCGGTT-31
pD(-101/-117)Luc
— >ALTRP7 : 5'-CTAAACCGCAATAACCGCAT-3' 
<—ALTRP8 : 5'-CTAGTCCTTTGGGTTATGCA-3 '
pD(-118/-137)Luc
— ►ALTRP9 : 5 1 -CTCATGTTGCTAGGCAACTAA-3 ' 
<—ALTRP 10: 5 ' -AGGTTATGAGAGCATCAGCAA- 3 '
pD(-135/-181)Luc
— ►ALTRP 11: 5 ' -ATAACCCAAAGGACTAGCTCA-3 ' 
ALTRP 12: 5 1-TTTATAAAACCCCTCATAAAAAC-3 '
2.10. API Site Site-specific Mutants of pALTRLuc
Two pALTRLuc mutants, termed pALTR(AP1 Am)Luc and 
pALTR(APlBm)Luc, were generated by site-directed mutagenesis at either one of the 
two most downstream potential API sites of ALTR. These plasmids, provided by C. 
R. Madden, were constructed using the Altered Sites Mutagenesis System (Promega) 
as recommended by the manufacturer. Briefly, pALTRCAT (see 2.7.) was digested 
with Hind III, and the Hind HI fragment containing LTR was gel-purified, and 
inserted into Hind IE-digested pSELECT-1 mutagenesis vector (Promega) to create a
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phagemid pALTRselect. Competent JM109 E. coli cells were transformed with the 
phagemid. Correa clones that have LTR in the direaion of T7 transcription were 
screened by a-complementation and restriction digestions.
Next, single-stranded template DNA was prepared for a mutagenesis reaaion. 
Briefly, the transformed JM109 cells were cultured overnight in tryptone-yeast 
extraa-phosphate broth in the presence of 15 jig/ml tetracycline. One hundred jtl of 
the culture was diluted 50 times with the broth plus the antibiotic, vigorously shaken at 
37° C for 30 min, infected with helper phage R408, and cultured overnight. Culture 
supernatant containing the phagemid was harvested by centrifuging, and the phagemid 
was pelleted after being precipitated in a solution of 0.75 M ammonium acetate (pH
7.5) and 4% polyethlene glycol (MW 8,000). The pellet was resuspended in TE (pH 
8.0) (see APPENDIX 1) and extraaed with chloroform/isoamyl alcohol (24:1) to lyse 
the phage. The upper aqueous phase containing phagemid DNA was extraaed with 
phenol/chloroform, ethanol-precipitated, and dissolved in water.
The mutagenesis reaaion involving annealing, mutant strand synthesis with T4 
DNA polymerase, and ligation was performed as follows. The single-stranded 
template DNA (0.05 pmole) was incubated in 20 |al reaction volume with 0.25 pmole 
phosphorylated ampicillin repair oligonucleotide (supplied by the manufacturer), 1.25 
pmole phosphorylated upper strand of ALTR API Am or ALTR API Bm (for 
sequences, see section 2.4.), 20 mM Tris-Cl, pH 7.5, 10 mM MgCk, and 50 mM NaCl 
at 70° C for 5 minutes, and allowed to cool slowly to room temperature. This solution 
was then adjusted to 30 (il containing 23 mM Tris-Cl, pH 7.5, 6.7 mM MgCl2, 33 mM
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NaCl, 0.5 mM each dNTP, 1 mM ATP, 2 mM dithiothreitol (DTT), 10 units T4 DNA 
polymerase, and 2 units T4 DNA ligase followed by incubation at 37° C for 90 
minutes.
The reaction was used to transform competent BMH 71-18 mut S E. coli cells, 
a repair minus E. coli strain. Transformed cells were incubated at 37° C overnight in 
Luria-Betani (LB) medium containing 125 pg/ml ampicillin. Miniprep DNAs isolated 
from this overnight culture were used to transform competent JM109 E. coli cells, and 
the transformed cells were plated on LB plates plus ampicillin. Clones, termed 
pALTR(APlAm)select and pALTR(APlBm)select, were screened by sequencing. 
Finally, to construct luciferase plasmids, pALTR(APlAm)select and 
pALTR(APlBm)select were digested with Hind m , and Hind El fragments containing 
the mutated LTRs were gel-purified and inserted into Hind lH-digested 
pGL2-Enhancer Vector to form pALTR(AP1 Am)Luc and p ALTR( AP1 Bm)Luc 
luciferase plasmids. Clones were screened by restriction digestions. DNAs of the two 
API-site mutant luciferase plasmids were prepared and stored as described in section
2 .8 .
2.11. Gel Shift Assay
Double-stranded oligonucleotides and a 290-bp fragment were labeled and 
purified as follows. All probe oligonucleotides (about 4 pmoles each) were 5' 
end-labeled in 10 pi reactions containing 6 pi of [y-32P]ATP (specific activity, 4,500 
Ci/mmole; ICN) and 10 units of T4 polynucleotide kinase. After labeling, 1 pi of 500 
mM EDTA and 19 pi of water were added to each reaction. Then, 1 pi of each
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sample was removed and diluted in 0.2 M EDTA to determine radioactivity as 
described (Promega Corp., 1991). The specific radioactivity of labeled 
oligonucleotides was determined to be in a range of 7,000 to 17,000 cpm/finol 
oligonucleotide (cpm values were corrected based on the reference date of 32P). The 
remaining 29 pi portions of the samples were extracted with phenol/chloroform, 
ethanol-precipitated, run on two 20% (29:1 acrylamide:bisacrylamide) native 
polyacrylamide gels. The gels were visualized by autoradiography, and the bands of 
oligonucleotides were excised. Oligonucleotides were then isolated from the gel slices 
by the crush and soak method (Sambrook et al., 1989), and dissolved in 100 pi or 200 
pi of TE (pH 8.0) (see APPENDIX 1), of which 1 pi or 2 pi was counted with 2 ml of 
Liquiscint (National Diagnostics, Manville, NJ), in a liquid scintillation counter 
(Beckman) to calculate probe concentration, in terms of cpm/pl and finol/pl, of the 
purified oligonucleotides based on the specific radioactivity (cpm/finol) determined 
above of each oligonucleotide (cpm/finol). Finally, the purified oligonucleotides were 
diluted with TE (pH 8.0) to the same radioactivity per pi.
The 290-bp fragment (about 0.8 pmol) was 5' end-labelled in a 10 pi reaction 
containing 1 pi of [y-32P]ATP (specific activity, 7,000 Ci/mmole; ICN) and 5.3 units of 
T4 polynucleotide kinase. After labelling, 3.5 pi of 250 mM EDTA and 36.5 pi of 70 
mM Tris-Cl (pH 7.5) were added, and the reaction was extracted with 
phenol/chloroform, chloroform, and ether, and separated as four 100 pi fractions from 
free [y-32P] ATP by gel filtration using a NICK column (Pharmacia Biotech) 
equilibrated with 10 mM Tris-Cl (pH 7.5)/l mM EDTA. Radioactivity of the fractions
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was measured in a liquid scintillation counter after adding 5 |ft aliquot from each 100 
(ft fraction into 3 ml of Liquiscint. Specific radioactivity was 3,700 cpm/finol DNA 
(cpm value was corrected based on the reference date of 32P). The second fraction 
was only and directly used in gel shift assay.
Binding of the 290-bp probe to U937 nuclear extracts was carried out 
essentially as described (Nakabeppu et al., 1988). Varying amount (0.3 to 2.5 pg 
protein) of nuclear extracts was preincubated in a 25 (ft binding solution containing 10 
mM V-2-hydroxyethylpiperazine-Ar-2-ethanesulphonic acid (HEPES, pH 8.0)/17.5% 
glycerol (v/v)/0.1 mM EDTA/20 mM NaCl/4 mM MgCy2 mM DTT/2 mM 
spermidine (Sigma) with varying amounts (15 to 120 (ag/ml) of sonicated salmon 
sperm DNA (SS DNA) at room temperature for 15 minutes. One (ft of 32P-labelled 
DNA (6,000 cpm; about 1.5 finol probe DNA) was then added, and incubation was 
continued for a further 20 minutes.
Binding of oligonucleotide probes to U937 nuclear extracts was performed as 
described above with some modifications. All binding reactions were carried out in 25 
(il reaction mixtures containing 10 mM HEPES (pH 8.0)/17.5% glycerol (v/v)/0.1 mM 
EDTA/30 mM NaCl/4 mM MgClj/2 mM DTT/2 mM spermidine with 60 pg/ml of 
sonicated SS DNA. Nuclear extract (8 (ig protein) was preincubated under the 
binding condition at room temperature for 8 minutes. After this incubation, 3 pmol 
(1.4 to 1.7 |ft) of specific unlabelled competitor DNA was added and incubation was 
continued for a further 7 minutes. Then, 2 (ft of 32P-labelled DNA (43,000 to 53,000
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cpm: 8 to 16 fitiol probe DNA) was added, and incubation was continued for a further 
20 minutes.
Binding of oligonucleotide probes to c-Jun/API protein (Promega) was 
performed as described by Gabuzda et al. (1989) and as recommended by the 
manufacturer (Promega Corp., 1992a and 1992b) with modifications. All binding 
reactions were carried out in 25 pi reaction mixtures containing 25 mM HEPES (pH
7.5), 100 mM NaCl, 5 pg of BSA, 0.5 mM EDTA, 0.05% Nonidet P-40, 1 mM DTT,
5 pg/ml poly(dI-dC).poly(dI-dC). One footprinting unit of c-Jun (1.1 pg) was 
preincubated under the binding condition without labelled probe at room temperature 
for 15 minutes. Then, 7 pi of 32P-labelled DNA (55,000 to 61,000 cpm: 24 to 41 finol 
probe DNA) was added and incubation was continued for a further 20 minutes.
After the binding reaaion, 5 pi of 0.1% bromophenol blue in the binding buffer 
(Nakabeppu et al., 1988) containing 15 pg/ml sonicated SS DNA (5 pi of 80% 
glycerol in the case of c-Jun/API binding) was added to each reaction. The mixtures 
were immediately loaded onto a 1.5 mm-thick and 13.6 cm-long, 6% (59:1 
acrylamide:bisacrylamide) native polyacrylamide gel that had been prerun in 0.25x 
TBE (lx  TBE is defined as 89 mM Tris base/89 mM boric acid/2.5 mM EDTA) at 180 
V for 2 to 3 hr. The samples were run in fresh buffer at 375 V until the samples had 
entered the gel (7 to 10 minutes) and then at 180 V for 70 minutes (3 hours in the case 
of 290-bp binding) as described by Nakabeppu et al. (1988). The gel was 
subsequently dried and autoradiographed with intensifying screen at -70° C with 
XAR-5 film (IBI/Eastman Kodak Co., New Haven, CT).
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2.12. Determination of Relative Affinity of API Sites and TPA-induction Level
Relative affinity of putative API sites and the level of TPA-induction were 
determined by comparing shifted band intensities in gel shift experiments. Gels were 
marked with [y-32P]ATP at several positions, autoradiographed with XAR-5 films 
(IBI/Eastman Kodak), and shifted bands were cut out using the films as templates. 
Radioactivity of gel pieces were measured with 3 ml of Liquiscint (National 
Diagnostics) in a liquid scintillation counter (Beckman). Relative affinity was 
determined by dividing shifted-band radioactivity of each EIAV LTR API 
oligonucleotide by that of a consensus API oligonucleotide (Visna API). Induction 
level was calculated by dividing radioactivity of the band of the complex formed 
between each oligonucleotide and TPA-induced nuclear extract by radioactivity of the 
band of the complex formed between the oligonucleotide and uninduced nuclear 
extract.
2.13. DNase I Footprinting Analysis
Probe DNAs, ranging from 179 to 432 bp in length, were 32P-labeled at the 5' 
end of the upper strands of four EIAV LTRs or of the lower strand of the visna virus 
LTR as follows. Plasmids containing LTR sequences (see 2.6.) were digested with 
Hind IH (Sst I in the case of visna vims LTR-containing plasmid), and 
dephosphorylated with CIAP (Boehringer Mannheim). These dephosphorylated, 
linearized plasmid DNAs were labeled in 25 pil reactions with vacuum-dried 
[y-32P]ATP (specific activity, 4,500 Ci/mmole; ICN) corresponding to 25 pil by 
incubation with 20 units of T4 polynucleotide kinase (New England Biolabs) at 37° C
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
61
for 1 hour. After incubation, 1 (ft of 500 mM EDTA was added, and the reactions 
were extracted with phenol/chloroform, chloroform, and ethanol-precipitated. DNAs 
were digested with a second enzyme, EcoR. I (Xho I in the case of the visna virus LTR 
plasmid), and extracted with phenol/chloroform, chloroform, ethanol-precipitated, and 
dissolved in 10 (il of TE (pH 8.0). To isolate the labeled probe, the DNA samples 
were run at 100 V for 3.5 hours on 5% (29:1 acrylamide:bisacrylamide) native 
polyacrylamide gels that had been prerun at 100 V for 80 minutes. The gels were 
autoradiographed with XAR-5 films for 10 minutes. The bands containing the probe 
DNAs were excised using the developed films as templates. The DNAs were isolated 
by the crush and soak method (Sambrook et al., 1989), dissolved in 200 or 300 p.1 of 
TE (pH 8.0), and stored at 4°C. The radioactivity of the DNAs was determined by 
counting 2 p.1 in Liquiscint in a liquid scintillation counter (Beckman). The DNA 
concentration of the probe DNAs were determined by comparing fluorescence of the 
probes with that of a molecular weight standard DNA (Lambda DNA-5s/E II Digest; 
New England Biolabs) that was run in a series of different DNA concentrations in 
agarose gels containing EtBr. The specific radioactivity of labelled probes was 
determined to be in a range of 12,000 to 21,000 cpm/finol DNA (cpm values were 
corrected based on the reference date of 32P). From each probe, 8 x 105cpm (based on 
32P reference date) was used for preparation of sequencing ladders by the chemical 
sequencing method of Maxam & Gilbert (1980), using the G+A-specific reaction. The 
sequencing ladders were prepared using a chemical sequencing kit (DuPont Biotech, 
Wilmington, DE) according to the conditions recommended by the manufacturer.
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After the chemical reactions the samples were lyophilized and stored at -70° C. An 
aliquot (120 to 200 (ol) from each remaining labeled probe solution was diluted with 
TE (pH 8.0) to 2.5 fmol/(ji (15,200 to 26,100 cpm/pl: cpm was corrected based on 32P 
reference date) for use in binding reaction. These diluted aliquot were stored at 4 °C 
until use.
Binding reactions including U937 cell nuclear extracts were performed as 
described (Gabuzda et al. 1989) with modifications. The binding reaction was done in 
a 50 [il volume containing 25 mM HEPES (pH 7.5), 1 mM DTT, 0.5 mM EDTA, 
0.05% Nonidet P-40, and 100 mM NaCl plus KC1 which is from the nuclear extracts, 
20 (standard in this dissertation) to 80 (ig/ml of poly(dI-dC).poly(dI-dC) or 10 |ig/ml 
sonicated SS DNA, 20 |ig (for samples) or 70 (ig (for BSA controls) of BSA, 14 pmol 
(930 to 2800 x) of a specific unlabelled competitor oligonucleotide where indicated,
70 (standard in this dissertation) or 100 fig of nuclear extract for samples, and 2 to 6 
(il (5 to 15 finol) of probe DNA. The binding reaction was incubated at room 
temperature (20° to 22° C) for 20 to 25 minutes before adding probe DNA and for 30 
to 75 minutes after adding probe DNA. Then, the reaction was adjusted to 5 mM 
MgCL and 2.5 mM CaCl2 by adding 2.8 (il of a solution containing 100 mM MgCL, 
and 50 mM CaCl,, and DNase I was added (5.0 to 8.8 ng for BSA controls; 520 to 
1,050 ng for samples) exactly for 60 seconds at room temperature.
Binding reactions including the purified c-Jun/API protein (Promega) were 
performed as described (Gabuzda et al. 1989) with modifications. The binding 
reaction was done in a 50 (il volume containing 25 mM HEPES (pH 7.5), 1 mM DTT,
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0.5 mM EDTA, 0.05% Nonidet P-40, and 100 mM NaCl plus KC1 which is from the 
API protein solution, 20 pg/ml of poly(dI-dC).poly(dI-dC), 20 pg (for both BSA 
controls and samples) of BSA, 14 to 56 pmol (400 to 1600 x) of a specific unlabelled 
competitor oligonucleotide where indicated, one footprinting unit of c-Jun/AP 1 
protein for samples, and 14 pi (35 finol) of probe DNA. The binding reaction was 
incubated at room temperature (20° to 22° C) for 15 to 30 minutes before adding 
probe DNA and for 30 to 65 minutes after adding probe DNA. Then, the reaction was 
adjusted to 5 mM MgCL, and 2.5 mM CaCL, by adding 2.8 pi of a solution containing 
100 mM MgClj and 50 mM CaCL,, and DNase I was added (7.8 ng for BSA controls; 
13 to 17 ng for samples) exactly for 60 seconds at room temperature.
To stop the nuclease digestion reaction, an equal volume (55.8 pi) of 200 mM 
NaCl/20mM EDTA/1% SDS/40 pg/ml tRNA/100 pg/ml proteinase K was added, and 
the reaction tube was placed in a dry ice-ethanol bath until all samples were treated 
with DNase I. The reactions were then incubated for proteinase K digestion at 45° C 
for about 30 minutes. The DNA was extracted with phenol-chloroform twice, 
ethanol-precipitated, washed with 70% ethanol, and vacuum-dried. The entire DNA 
pellet was dissolved (about 6,000 to 75,000 cpm by Cerenkov counting; if all the 
samples of a footprinting had higher radioactivity than 75,000 cpm, only a portion was 
dissolved; the maximum radioactivity variation in a footprinting was 2.7 times between 
highest and lowest samples) in 3 pi of formamide loading buffer (Earl et al., 1987) and 
analyzed with markers of about half to two times radioactivity on an 8 M urea-8%
(19:1 acrylamide:bisacrylamide) polyacrylamide gel. After electrophoresis, the gel was
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fixed in 10% methanol/10% acetic acid (Sambrook et al., 1989) for 20 minutes, 
vacuum-dried, wrapped in a single layer of plastic wrap, and autoradiographed with
intensifying screen at -70° C with XAR-5 film (IBI/Eastman Kodak).
2.14. Time Course Study of the Transient Gene Expression of Luciferase 
Activity in U937 Cells
U937 cells were transiently transfected with pALTRLuc (see 2.8.), as 
described (Pahl et al., 1991) with modifications. Cells were maintained at a cell 
density between 0.5 x 106/ml and 1.1 x 106/ml, and split to 3 x 105/ml 19 hours before 
transfection. At the time of transfection, cell cultures having a cell density of 7.3 x 
105/ml were harvested by centrifugation at 210 x g for 4 min at room temperature.
Cells were washed twice with room-temperature RPMI-1640 medium containing 
neither FCS nor L-glutamine. Cells were then resuspended at 2.8 x 107/ml in 
room-temperature RPMI-1640 medium containing neither FCS nor L-glutamine but 
containing 40 pg/ml pSV/3-Galactosidase Control Vector (Promega) as carrier, and 
the cell suspension was divided into Gibco BRL 0.4-cm electroporation cuvettes (0.5 
ml/cuvette). Twenty micrograms of luciferase plasmid DNA in water (0.86 pg/pl) 
were added per cuvette. The cell suspension was then incubated for 11 to 18 minutes 
at room temperature, and electroporated at 305 to 310 volts using a Cell-Porator 
Electroporation System (Gibco BRL) that was set to 800 pF, "Low" ohm, and "Fast" 
charge rate. The cuvettes were transferred to an ice bath immediately after 
electroporation, and incubated for 20 minutes. All the cells electroporated were then 
diluted 20 times with complete medium (RPMI-1640 medium supplemented with 10% 
FCS and 50 pg/ml gentamicin), and combined in a 100-mm diameter tissue culture
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dish. The cells were divided into 100-mm dishes (5 ml per dish) and diluted finally to 
30 ml with complete medium. For induction, 30 nM TP A (final concentration) was 
then added using 30 pM TP A that was prepared by diluting, in complete medium, a 
stock solution of 1.6 mM TP A in dimethyl sulfoxide. Cells were incubated at 37° C 
with 5% C02 for indicated times.
Luciferase activity was measured as follows. Transfected U937 cells were 
harvested by scraping and by centrifuging at 210 x g for 4 minutes at room 
temperature. The cell pellet was resuspended in 1 ml of 4° C PBS, pH 7.4, and 
centrifuged at 12,000 x g for 10 seconds. This wash step was repeated once more.
The cell pellet was then resuspended in 300 pi (or 200 pi to find any effect of lysis 
buffer volume) of room-temperature reporter lysis buffer (RLB; Promega) by shaking 
for 2 minutes. The resuspended cells were lysed by gentle shaking at room 
temperature for 15 minutes (or by two cycles of rapid freeze-thaw to find any effect of 
freeze-thaw: frozen by immersing sample tubes in a dry ice/ethanol bath for 5 minutes 
and melted by shaking at room temperature for 8 minutes), kept on ice for 3 minutes, 
shaken briefly, and centrifuged at 12,000 x g for 5 minutes at 4° C. Immediately after 
centrifugation, 200 pi (130 pi for 200 pi lysis) of the supernatant, hereafter referred to 
as cell extract, was removed carefully, and frozen in liquid nitrogen and stored at -70° 
C. To determine luciferase activity, 2 pi of the cell extract were placed into an 
autoclaved polypropylene vial (Omni-Vial; Wheaton, Inc., Millville, NJ) containing 18 
pi of room-temperature RLB containing 1 mg/ml BSA. Sample was mixed with 100 
pi of Luciferase Assay Reagent (Promega) that had been equilibrated to room
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temperature for more than 30 minutes as recommended by the manufacturer. The 
sample vial was inserted into a 20 ml scintillion vial, and put on an iron metal (a stool) 
for 1 minute to remove any static charge, and counted for 1 minute in a liquid 
scintillation counter (Beckman LS 6800) in single photon counting mode. It is 
important that in counting plastic gloves should not be worn.
2.15. Transient Transfection of U937 Cells
U937 cells were transiently transfected as described (Pahl et al., 1991) with 
modifications. Cells were maintained between 0.5 x 106/ml and 1.5 x 10s/ml, and split 
to 3 x lOVml 16 to 18 hours before transfection. At the time of transfection, cells 
having cell density of 4.6 x 105/ml to 5.2 x 10s/ml were harvested by centrifugation at 
210 x g for 4 min at room temperature. Cells were washed twice with total 60 ml of 
room-temperature RPMI-1640 medium containing neither FCS nor L-glutamine by 
resuspending and by centrifuging as above. Cells were then resuspended at 2.8 x 
l07/ml in room-temperature RPMI-1640 medium containing neither FCS nor 
L-glutamine but containing 40 pg/ml pSV/p-Galactosidase Control Vector (Promega) 
as carrier, and the cell suspension was divded into Gibco BRL 0.4-cm electroporation 
cuvettes (0.5 ml/cuvette). Twenty micrograms of luciferase plasmid DNA in water 
(0.55 to 1.14 pg/pl) were added per cuvette. The cell suspension was then incubated 
for 13 to 25 minutes at room temperature, and electroporated under the identical 
condition as described above (see 2.14.). The cuvettes were transferred to ice baths 
immediately after electroporation, and incubated for 25 minutes. The cells were 
transferred to 9.5 ml of complete medium (RPMI-1640 medium supplemented with
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10% FCS and 50 pg/ml gentamicin) in a 100-mm diameter tissue culture dish. For 
induction, half volume (5 ml) of the electroporated cells was then removed to another 
dish, diluted to 20 ml with complete medium, and 30 nM TP A (final concentration) 
was added using 20 pi of 30 pM TP A that was prepared by diluting, in complete 
medium, a stock solution of 1.6 mM TP A in dimethyl sulfoxide. For uninduction, the 
other half volume of the cells was similarly diluted to 20 ml. Cells were incubated at 
37° C with 5% C02 for 8 hours. Transfection was performed 3 times on separate 
days.
2.16. Luciferase Assay of Mutant LTRs
Luciferase assays were performed as follows. Transfected U937 cells were 
harvested by scraping and by centrifuging at 210 x g for 3 minutes at room 
temperature. The cell pellet was resuspended in 1 ml of 4° C PBS, pH 7.4, and 
centrifuged at 12,000 x g for 10 seconds. This wash step was repeated once more.
The cell pellet was then resuspended in 300 pi of room temperature RLB (Promega) 
by shaking for 2.5 minutes. The resuspended cells were lysed by gentle shaking at 
room temperature for 15 minutes, kept on ice for 3 minutes or longer (up to 1 hour), 
shaken briefly, and centrifuged at 12,000 x g for 5 minutes at 4° C: 4 or smaller 
number of tubes were centrifuged each time to quickly remove their supernatants. 
Immediately after centrifugation, 200 pi of supernatant (i.e., cell extract) was removed 
carefully, and diluted 10 times with RLB (visna virus samples were diluted 10 times 
again with RLB containing 1 pg/pl BSA). Four microliters of the 10 x diluted (visna 
virus samples: 100 x diluted) extract were then added into an autoclaved
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polypropylene vial (Omni-Vial; Wheaton, Inc., Millville, NJ) containing 16 pi of 
room-temperature RLB containing 1 pg/pl BSA. Sample was mixed with 100 pi of 
Luciferase Assay Reagent (Promega) that had been equilibrated to room temperature 
for more than 30 minutes as recommended by the manufacturer. The sample vial was 
inserted into a 20 ml scintillion vial, and put on an iron metal (a stool) for 1 minute to 
remove any static charge, and counted for 1 minute in a liquid scintillation counter 
(Beckman LS 6800) in single photon counting mode. Time between cell harvesting 
and luciferase activity measurement in the three luciferase assays was similar.
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CHAPTER 3 
RESULTS AND DISCUSSION
Results are presented in two sections, first the physical and then the functional 
characterizations of the U3 region of EIAV LTR.
3.1. Physical Characterization of the U3 Region of EIAV LTR
In this section, the U3 region of 4 EIAV LTRs (A, V470, V3291, and P LTRs) 
(Fig. 5) is characterized by DNase I footprinting and gel shift assays using uninduced 
and TPA-induced U937 nuclear extracts. c-Jun/APl was also used for the 
characterization of API sites.
3.1.1. Demonstration by Gel Shift Assays of the Existence of Transcription
Factor Binding Site(s) in the Prototype EIAV LTR
As the first step of the study, a gel shift assay was performed as described 
(section 2.11.) with the Mnl I-&n/3A 1290-bp PLTR fragment that has the maximum 
size obtainable by using restriction enzymes commercially available at the time of the 
experiment. The purposes of the assay were to find whether the EIAV LTR has any 
transcription factor binding sites, and to optimize gel shift assay conditions. Fig. 6 
shows that all sample lanes (lanes 2 to 13) exhibit a band (marked Complex) of 
DNA-protein complex with a prominent retardation in mobility. This retardation 
indicates that PLTR contains at least one transcription factor binding site. Compared 
with lanes including uninduced nuclear extract (lanes 2 to 5), lanes including 
TPA-induced nuclear extract (lanes 6 to 9) show considerably higher band intensity. 
This suggests that TP A induced more binding activity. Comparing lanes 10 to 13, it 
was possible to determine an optimum nuclear extract concentration at fixed
69
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Fig. 5. Alignment of transcription factor binding sites on four EIAV LTRs footprinted 
in this study. (A) The sequences of the last 3 LTRs were aligned relative to that of 
ALTR (A), the LTR of the FDD cell-adapted strain of the prototype EIAV. The 
sequences between nucleotide (nt) -38 to -140 of the 4 LTRs are also shown in Fig. 
5B. The numbers indicate nt positions relative to the transcription initiation site (+1) 
of ALTR. The varient (V470 and V3291) LTRs were derived from the EIAV isolates 
during the two different febrile episodes of a pony experimentally-infected with the 
prototype EIAV (Payne et al., 1987). P represents the prototype LTR. Transcription 
factor binding core sequences are indicated in bold. Sequences protected strongly by 
U937 monocyte/macrophage nuclear extracts (Figs. 8 and 9) are double underlined. 
Sequences protected strongly by human c-Jun/APl (Figs. 12 and 13) are marked 
beneath them with asterisks. The API sites downstream of MDBP and the 
most-upstream PU. 1 sites in A, V470, and V3291 LTRs were weakly protected by the 
U937 nuclear extracts (Fig. 9). The API sites upstream of MDBP were protected by 
c-Jun/APl only. The putative Oct-1 (Fig. 8) and C/EBP (Fig. 9) sites, and the TATA 
box are indicated. The PEA2 site centered at +16 was not protected in this study, but 
has been shown to be protected with the nuclear extract from canine osteosarcoma 
cells (Carvalho and Derse, 1993a). Footprints of the other two PEA2 sites (Figs. 8 
and 9) are indicated. In the last 3 LTRs, strongly protected regions that are different 
in nt sequence from those of ALTR are also marked. (B) For structural comparison 
among the 4 LTRs without spacing in sequence, the transcription factor binding sites 
protected by U937 nuclear extracts upstream of the TATA box were redrawn from 
panel A. The name(s) of the binding site(s) in the hypervariable region between the 
conserved PEA2 and API sites are overlined.
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Probe: P-182/+108
Nuc Ext: - Uninduced TPA-induced
Nuc Ext Cone (ng/ml): 0 50 50 12.5 25 50 100
SS DNA (pg/ml): 15 15 30 60 120 15 30 60 120 60 60 60 60
1 2 3 4 5 6 7 8 9 to 11 12 13
Complex
Fig. 6. Binding of the 290-bp probe derived from EIAV PLTR to U937 nuclear 
extracts. The gel shift assay (25 pi binding reaction) was performed as described in 
MATERIALS AND METHODS with about 1.5 finol 32P-labelled probe at the 
indicated concentration of uninduced or TPA-induced U937 nuclear extract, and 
sonicated salmon sperm (SS) DNA as nonspecific carrier DNA. The positions of the 
bound DNA-protein complex (Complex) and of the unbound freely migrating probe 
(Free) are indicated.
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concentrations of probe DNA and sonicated SS DNA as nonspecific carrier DNA An 
optimum gel shift condition is indicated by the band patterns of lanes 11 and 12, which 
show the presence of a ditinctive, intense DNA-protein complex band well-separated 
from the free probe without significant smearing.
For another gel shift assay, the Hind HI-£coR 1432-bp fragment (see 2.5.) 
was digested with Alu I at nt -97 of PLTR. The resulting Hind lH-Alu 1170-bp 
fragment that contains the 5' half of the U3 region and Alu 1-EcoK 1262-bp fragment 
that contains the 3' half of the U3 region were gel-purified and used with TPA-induced 
and uninduced U937 nuclear extracts in the gel shift assay. It was found that the 
262-bp fragment could bind strongly, but that the 170-bp fragment bound only weakly 
(data not shown). This suggests that most of transcription factor binding sites are 
located in the 3' half of the U3 region of PLTR.
3.1.2. Demonstration of API Activity in U937 Nuclear Extracts by DNase I
Footprinting of Visna Virus LTR
To test the activity of U937 nuclear extract preparations, a fragment of visna 
virus LTR, which contains a number of transcription factor binding sites including API 
sites, was used as a test probe for DNase I footprinting (Fig. 7). This probe is 167 bp 
(nts -140 to +27) in length and contains a consensus API site (5' TGACTCA 3') and 
two putative API sites (Gabuzda et a l, 1989). Clearly protected regions were 
observed (Figs. 7A and 7B). One of the protected regions contains the consensus API 
site from nt -48 to -54. This result indicates that the nuclear extract preparations 
contained at least functional API proteins.
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Fig. 7. Existence of API activity in U937 nuclear extracts demonstrated by DNase I 
footprinting of visna virus LTR. Footprinting was performed as described in 
MATERIALS AND METHODS: thel79-bp probe DNA containing nts -140 to +27 
of visna virus LTR was 32P-labeIled at the 5' end of lower strand, incubated with 
nuclear extracts (50 pi binding reaction), and treated with DNase I for 1 min. The 
resulting DNA fragments were resolved on an 8 M urea-8% polyacrylamide gel. (A) 
Lane G+A, G and A Maxam and Gilbert sequencing ladder of the same fragment run 
in parallel; lane 1, with 1.4 mg/ml of BSA and no nuclear extract; lanes 2 to 5, with 1.4 
mg/ml of uninduced (-TPA) or TPA-induced (+TPA) U937 nuclear extract; lane 6, 
with 2.0 mg/ml of the induced nuclear extract. The concentrations of 
poly(dI-dC).poly(dI-dC) as carrier DNA are indicated. The protected regions are 
indicated on the right by brackets with nt numbers relative to the transcription 
initiation site (+1). API core sequences are indicated on the left. (B) DNase I 
footprinting was performed as in panel A except that competitors were added as 
indicated: 930-fold molar excess (14 pmol) of competitor oligonucleotides were added 
and the reaction preincubated for 15 min as in panel A before the probe DNA was 
added. Nt sequences of oligonucleotides used here are shown in Table 1: competitor 
Visna API is a 19-bp oligonucleotide spanning nts -41 to -59 of visna virus LTR and 
thus contains the consensus API core sequence (5‘ TGACTCA 3'), while competitor 
PLTR API is a 19-bp oligonucleotide spanning nts -45 to -63 of PLTR and contains a 
putative API site (Carvalho and Derse, 1993a). Nt -60 appeared to be DNase 
I-hypersensitive in the footprinting.
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It is also clear that the footprinting condition was optimized well in DNase I 
concentration, yielding appropriate relative band intensities for comparison between 
the upper and lower parts of each lane, and among lanes. The footprinting patterns 
also revealed that TPA-induction resulted in a slightly stronger protection (Fig. 7A and 
7B, lanes 2 and 3), indicating an increase in API activity by TPA treatment of U937 
cells. The 19-bp "Visna API" competitor oligonucleotide spanning nts -41 to -59 of 
visna virus LTR (Shih et al., 1992) contains the consensus API site. This 
oligonucleotide could compete specifically for API-binding activity with the consensus 
API site but not with a different factor-binding region from nt -84 to -107 (Fig. 7B, 
lanes 3 and 4, and lanes 7 and 8). Another competitor, the 19-bp PLTR API 
oligonucleotide containing a putative API site (5‘ TGACGCG 3') (Carvalho and 
Derse, 1993a) could also specifically compete, though weaker, with the consensus 
API site (Fig. 7B, lanes 3 and 5, and lanes 7 and 9).
3.1.3. Localization of Transcription Factor Binding Sites in the U3 Region of
EIAV LTR
In this section, the transcription factor binding sites in the U3 region identified 
by using DNase I footprinting and gel shift assays are presented in the order of Oct-1, 
MDBP, PEA2, C/EBP, PU.l, and API sites. A possible NRE is described in section 
3.2., since it was identified only by the transient gene expression assays using deletion 
mutants.
3.I.3.I. Putative EIAV Oct-1 Region (nts -125 to -144 of ALTR)
A putative binding site of the ubiquitous transcription factor Oct-1 (reviewed 
by Herr, 1992) [also termed nuclear factor A l (NF-Al)/octamer-binding transcription
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factor 1 (OTF-1)/ nuclear factor III (NFHI)/qctamer binding protein of 100 kDa 
(OBPIOO) (Singh et al., 1986/Staudt et al., 1986; Fletcher et al., 1987; Pruijn et al., 
1986/O'Neill and Kelly, 1988; Sturm et al., 1987)] was identified in ALTR (Fig. 8). 
This protected site has a sequence similarity to the consensus octamer motif 
(ATTTGCAT: Locker, 1993) and to Oct-1 binding sequence of SV40 enhancer 
(CTTTGCATA: Rosales et al, 1987; Pruijn et al, 1987) (nts identical to those of the 
ALTR are underlined). This putative Oct-1 site was not competed by API and NF-kB 
oligonucleotides (Fig. 8, lanes 4 and 5), supporting the specificity of the Oct-1 site. 
Protection of the region was not affected by TP A treatment of U937 cells (compare 
lanes 2 and 3, or lanes 7 and 8 in Fig. 8). This may be due to the ubiquitous 
distribution of Oct-1 factor, although this factor is inducible by TP A (Faisst and 
Meyer, 1992). The nt -135 of the Oct-1 site, which is C in ALTR but T in the other 3 
LTRs, must be a critical base in binding Oct-1 recognizing factor(s), since the 
corresponding region of PLTR, V470LTR, and V3291LTR did not make the footprint 
(data not shown).
3.1.3.2. EIAV MDBP Region (nts -94 to -114 of ALTR)
The 4 EIAV LTRs have the same footprints in the MDBP binding regions 
(Figs. 8 and 9 A to 9D) of the same nt sequence (Fig. 5B). In the case of EIAV, these 
are the first MDBP footprints ever observed. The protected 13-bp core sequence (Fig. 
5) is identical to that of the MDBP site of polyomavirus enhancer (Ostapchuk et al., 
1986) and is nearly identicsal to the MDBP consensus sequence (see 1.1.3.5.). No 
difference was seen between MDBP footprints with uninduced and TPA-induced
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Fig. 8. DNase I footprinting of 5' half of the EIAV ALTR U3 region with U937 
nuclear extracts. Footprinting was performed as described in MATERIALS AND 
METHODS: 380-bp probe DNA containing the entire 323-bp EIAV ALTR was 
32P-labelled at the 5' end of upper strand and subjected to competition DNase I 
footprinting as in Fig. 7B. Nt sequences of oligonucleotides used are shown in Table 
1: PLTR API sequence was also described in Fig. 7B legend; 22-bp NF-kB 
oligonucleotide contains mouse kB element and was used as nonspecific competitor. 
Lane G+A G and A Maxam and Gilbert sequencing ladder; lanes I and 6 included 1.4 
mg/ml of BSA and no nuclear extract; lanes 2 and 7 included uninduced (-TPA) U937 
nuclear extract 2.0 mg/ml and 1.4 mg/ml, respectively; lanes 3 and 8 included 
TPA-induced (+TPA) U937 nuclear extract 2.0 mg/ml and 1.4 mg/ml, respectively; 
lanes 4 and 5, 2800-fold molar excess (14 pmol) of competitor oligonucleotides were 
added and the reaction preincubated for 15 min before the probe DNA was added.
The concentrations of poly(dI-dC).poly(dI-dC) as carrier DNA are indicated. The 
protected regions located upstream of nt -75 are indicated on the right by brackets 
with nt numbers relative to the transcription initiation site (+1). For PEA2 and MDBP 
sites, core sequences are indicated by brackets.
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Fig. 9. DNase I footprinting of 3' half of the U3 region of the four EIAV LTRs with 
U937 nuclear extracts. In panels A to F, lane G+A G and A Maxam and Gilbert 
sequencing ladder; lanes 1 and 4 used 1.4 mg/ml of BSA and no nuclear extract; lanes 
2 and 5 used 1.4 mg/ml of uninduced (-TPA) U937 nuclear extract; lanes 3 and 6 used 
1.4 mg/ml of TPA-induced (+TPA) U937 nuclear extract. Footprinting was 
performed as described in MATERIALS AND METHODS: probe DNAs containing 
5' deletion up to Alu I site (PLTR: -97; ALTR: -118; V470LTR: -115; V3291LTR: 
-124) in the LTRs were 32P-labelled at the 5' end of upper strands and subjected to 
DNase I footprinting with 20 pg/ml of carrier poly(dI-dC).poly(dI-dC) DNA in the 
panels A to D or with 10 pg/ml of sonicated SS DNA in the panels E and F. In panels 
A to D, except PEA2 sites, which are indicated in Fig. 8, protected regions are 
indicated on the right by brackets with nt numbers relative to the transcription 
initiation site (+1). In panels E and F, only putative C/EBP-protected region (other 
protected regions are indicated in panels A to D) is indicated. The "w" in PU. 1 w and 
APlw indicates that the footprints were weak. For API sites, only core sequences are 
indicated on the left, since boundaries of footprints were uncertain. TATA box is 
indicated, though it was not footprinted. Panels A to F were prepared from the same 
gel.
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nuclear extracts, suggesting that MDBP is expressed equally in both monocyte and 
macrophage cells of U937, in agreement with the ubiquitous distribution of MDBP. 
The protection of MDBP sites was not interfered by oligonucleotides PLTR API and 
NF-kB (Fig. 8, lanes 4 and 5), indicating that the MDBP sites were bound specifically 
by MDBP-recognizing factor(s).
It was previously shown by gel shift assays that oligonucleotides containing 
the EIAV MDBP site can form specific complexes with various nuclear extracts 
including human monocyte (THP-1) cells (Carvalho and Derse, 1993a).
3.I.3.3. EIAV PEA2 Region (nts -76 to -99 of ALTR)
In EIAV ALTR, the region from nt -76 to -99 contains a tandem repeat of a 
potential PEA2 sequence (5' AACCGCA 3'). The footprints of the two putative 
PEA2 sites formed with uninduced and TPA-induced U937 nuclear extracts are shown 
in Fig. 8. The intensities of footprints with both nuclear extracts appear similar.
In the 4 EIAV LTRs, the region from nt +7 to +24 contains, in reverse 
orientation, a sequence identical to the polyomavirus PEA2 site. However, this 
sequence was not protected with U937 nuclear extracts, suggesting that this sequence 
might have lower affinity than the two upstream PEA2 sequences. This positional 
difference in PEA2 affinity may be supported by an observation made by Carvalho and 
Derse (1993a) that when the tandem PEA2 sites were individually mutated, the CAT 
activities of CAT reporter gene constructs of the two PEA2 mutants were 11 times 
different from each other in uninduced HeLa cells. Another possibility is that PEA2 
binding activity is not high in U937 cells. Cell-dependent PEA2 activity has been
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observed by two groups: Carvalho and Derse (1993a) observed a very different level 
of PEA2 binding activity among different cell types, and by gel shift assay, Maury 
(1994) even observed no binding of the most upstream PEA2 site with nuclear extracts 
of macrophages that were derived from horse monocytes. An additional alternative is 
that both possibilities may be simultaneously considered. In spite of detailed studies 
on the EIAV PEA2 sites by Carvalho and Derse (1993a), it can not be totally excluded 
that the sites may be C/EBP sites (Thompson et al., 1994). Supershifting with 
antibody against PEA2 or gel shifting with purified PEA2 protein may help define 
these sites.
3.1.3.4. Putative EIAV C/EBP Binding Site (nts -16 to -24 of ALTR)
C/EBP (CCAAT/enhancer binding protein) binds to both CCAAT homologies 
and many viral enhancers that contain a degenerate nonamer sequence, 
TGTGG(A/T)(A/T)(A/T)G (reviewed by Johnson and McKnight, 1989). Studies on 
other genes revealed that C/EBP has a rather loose binding specificity, and that a set of 
known genes is more useful than a consensus sequence, T(G/T)NNG(T/C)AA(G/T), 
for searching C/EBP sites (Locker, 1993). In the EIAV LTR, a 9-bp sequence (51 
AAGTGCTTG 3') was protected when sonicated SS DNA was used as carrier DNA 
(Figs. 9E and 9F). This sequence shows some sequence similarity to the C/EBP site of 
region C in mouse a t-antitrypsin gene enhancer (al-AT-C, Grayson et al., 1988a).
The following al-AT-C sequence is shown for comparison with the footprinted LTR 
sequence: 5' TAACTGCTTTGCTTAAGAC TCC 3’; italicized is the al-AT-C 
sequence similar to the protected 9-bp LTR sequence; underlined are nts identical to
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
88
those of the 4 EIAV LTRs; bold-faced is the region important for protein binding 
found by a combination of both methylation protection and interference assays 
(Grayson et al., 1988b). To my knowledge, this putative C/EBP site of EIAV LTR is 
described for the first time.
3.I.3.5. EIAV PU.l Regions (nts -31 to -47, and nts -59 to -70 of ALTR)
From the 4 EIAV LTRs, a total o f 8 putative PU.l binding sites were 
footprinted (Figs. 9A to 9D). Each site had a similar footprint intensity when 
uninduced and TPA-induced U937 nuclear extracts were compared, indicating that 
U937 monocyte and macrophage cells express PU.l protein in similar abundance. 
There are 5 different PU.l sequences (Fig. 10) among the 8 putative PU.l sites. 
Interestingly, all the PU. 1 sequences have the same directionality. This is evidenced by 
the DNase I hypersensitive nucleotides (Fig. 10) that appear as the strong bands within 
the PU. 1 footprints (Figs. 9A to 9D), and that are the same distance from the ets core 
motif (5‘ TTCC 3'). The directionality is also supported by the fact that Ets proteins 
bind as monomers to DNA sequences (Janknecht and Nordheim, 1993), although 
PU. 1 has been shown to be functional in either orientation and either upstream or 
downstream of the CAT gene promoter (Klemsz et al., 1990). In addition, PU. 1 was 
shown to be able to bind simultaneously on two close PU. 1 sites without interfering 
each other (Fig. 9D).
PU. 1 sequences I, II, and V have been previously reported: an oligonucleotide 
containing a portion (nts -45 to -34) of sequence I was supershifted in gel shift assays 
with PU. 1 antiserum using unstimulated monocyte nuclear extracts from THP-1 and
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ets corei i 
-3 +1 +95' CACTTCCCCTTT 3': PU.l Consensus (upper case letters)
TTt TTtaaA of lower strand 
acg g
g
I: -47 AaCTTCCTGIUTTACA -31: All 4 EIAV LTRs (strong footprints)
II: -77 TAGTTCCGCATTT -65: V3291LTR (strong footprint)
III:’ -70 AGTICQACATIT -59: ALTR (weak footprint)
IV: -69 AGTTCCCCATTG -58: V470LTR (weak footprint)
V: -90 TAGTTCCTCAATA -78: V3291LTR (weak footprint)
Fig. 10. The footprinted PU. 1 sequences of the four EIAV LTRs. The PU. 1 
consensus sequence was adapted from Kominato et al. (1995) and Moreau-Gachelin 
(1994). The 16 PU.l binding sites compiled in these references, excluding PLTR 
PU. 1 sequence, were used to derive the consensus. The letters on the first line are nts 
with the highest frequency and those on the last line the lowest frequency. The upper 
case letters are nts with 25% or higher frequency. Nts were numbered from the ets 
core motif. Nts matched to the PU. 1 consensus sequence are underlined. Each PU. 1 
site had a single DNase I hypersensitive nt at +6 (marked with asterisk) identified by 
DNase I footprinting (Figs. 9 A to 9D). Nts at -71 of ALTR and -70 of V470LTR are 
G's.
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U937 cells (Carvalho and Derse, 1993b). Gel shift assays demonstrated that an 
oligonucleotide containing sequence II could be specifically shifted with THP-1 
monocyte nuclear extract (Carvalho et a l, 1993) or supershifted with PU.l antisera 
and primary horse macrophage nuclear extract (Maury, 1994). An oligonucleotide 
containing sequence V could also be supershifted with PU.l antiserum and primary 
horse macrophage nuclear extract (Maury, 1994). The putative PU. 1 binding
sequences HI and IV observed in this study (Fig. 10) have not been reported before.
3.I.3.6. Putative EIAV API Regions (nts -51 to -57, nts -71 to -77, nts -114 to 
-120, and nts -148 to -154 of ALTR)
Studies on binding of potential API sites are described in the following order: 
DNase I footprinting analyses with U937 nuclear extracts and then with c-Jun/APl 
which is a Jun/Jun homodimer, gel shift assays with c-Jun/APl and then with U937 
nuclear extracts, and determination of the relative affinities of the putative API sites 
and the TPA-induction level of API activity.
(1.) DNase I Footprinting with U937 Nuclear Extracts
Potential API sites footprinted with U937 nuclear extracts are shown in Figs. 
9A to 9D. In this footprinting experiment, the same batches of nuclear extracts used 
for the visna LTR footprintings (Fig. 7) were employed. However, there were only 
weak API footprints (Figs. 9A to 9D). Each LTR produced 2 weak API footprints 
except PLTR, which produced only 1 weak footprint. All the 7 API sites, which have 
3 unique API core sequences (Fig. 5B), are flanked very closely with other elements 
(Figs. 5B, and 9A to 9D). Protection of the 7 API sites are supported by the 
following observations: (i) TG dinucleotides of the API core sequences of the upper
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strands were always protected in spite of the fact that the core sequences were closely 
flanked by different elements {i.e., PEA2 and PU.l, PU.l and PU.l, PU.l and API, or 
API and PU.l in the 5' to 3' direction) (Figs. 9A to 9D); (ii) nts of the 7 API sites at 
the downstream C position of the consensus API sequence (51 TGACTCA 3') always 
appeared as a band (Figs. 9A to 9D) as in the DNase I footprinting of the consensus 
API sequence (Fig. 7A; Gabuzda et al., 1989); (iii) TPA-induction resulted in slightly 
stronger band intensity for nts of the 7 API sites at the two C positions of the 
consensus API sequence (Figs. 9A to 9D), which indicates enhanced cleavages 
presumably due to stronger binding activity produced after the TPA treatment. The 
specificity of the API sites were next examined further by footprintings with 
c-Jun/APl and by gel shift assays with c-Jun/APl and with nuclear extracts, as shown 
below.
(2.) DNase I Footprinting of LTRs of Visna Virus and EIAV with 
c-Jun/APl
To confirm specificity of the API sites of EIAV LTRs identified in Figs. 9A to 
9D, purified c-Jun/APl protein (Promega) was used in DNase I footprinting. First, 
the c-Jun/APl was tested for its DNA-binding specificity using the visna virus LTR.
As shown in Fig. 11, the c-Jun/APl had a strong binding activity to the API consensus 
sequence (site A), and the footprint appeared slightly smaller size than that of 
footprints obtained with nuclear extracts (Fig. 7A). The c-Jun/APl even protected the 
two weak API sites (Fig. 11, sites B and C) which could not be protected with U937 
nuclear extracts (Figs. 7A and 7B). API binding to the three API sites was 
specifically competed by the consensus API oligonucleotide, Visna API, but not by
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Fig. 11. DNA-binding specificity of human c-Jun/APl demonstrated by DNase I 
footprinting of visna virus LTR. Footprinting was performed as described in 
MATERIALS AND METHODS: 179-bp probe DNA containing nts -140 to +27 of 
visna virus LTR was 32P-labeIled at the 5' end of lower strand, incubated with 1 
footprinting unit (1.1 pg) of c-Jun/APl (Promega) in 50 pi binding reaction, and 
treated with DNase I for 1 min. The resulting DNA fragments were resolved on an 8 
M urea-8% polyacrylamide gel. Lane G+A, G and A Maxam and Gilbert sequencing 
ladder; lane 1 used 20 pg of BSA and no API protein; lane 2 used 1 footprinting unit 
of c-Jun/APl and 20 pg of BSA; lanes 3 and 4, competition DNase I footprinting 
performed similarly as in lane 2 except that 400-fold (14 pmol) or 800-fold (28 pmol) 
unlabelled competitor DNA was added and preincubated for 15 min before adding 
probe DNA. The 20 pg/ml of poly(dI-dC).poly(dI-dC) was used as carrier DNA. The 
protected regions are indicated on the right by brackets. API core sequences are 
indicated on the left. For sequences of Visna API and NF-kB, see the legends of Figs. 
7 and 8, respectively.
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unrelated oligonucleotide NF-kB even with twice more molar amount than that of 
Visna API. The c-Jun/APl, therefore, has API binding specificity.
When the entire ALTR was footprinted with c-Jun/APl, 6 sites were protected 
(Fig. 12). The strongly footprinted sites A and B correspond to the two API sites 
weakly footprinted with nuclear extracts (Fig. 9B). In all the six putative API sites, 
API binding was specifically competed by Visna API and AP1F (Fig. 12, lanes 3, 5, 6, 
and 7). Site A was least affected by AP1F, suggesting that site A has the strongest 
affinity for c-Jun/APl. In contrast with Visna API, the unrelated oligonucleotide 
NF-kB did not interfere the protection at sites A to D even with twice more molar 
amount than that of Visna API, but it could reduce the protection at sites E and F 
(Fig. 12, lane 4). These results suggest that the order of binding affinity of the 6 
putative API sites to c-Jun/APl are A > (B, C, and D) > (E and F).
Fig. 13 represents DNase I footprinting with c-Jun/APl of the same probes 
used in Figs. 9A to 9D. All the weakly protected API sites in Figs. 9A to 9D were 
strongly protected by c-Jun/APl. Protection of the API sites by c-Jun/APl was 
specifically interfered by Visna API but not by NF-kB even with twice more molar 
amount than that of Visna API. The results indicate strong specificity of the API 
sites. The specificity is further confirmed by competition of the API sites by PLTR 
API, AP1E, and AP1F for c-Jun/APl (Fig. 13A, lanes 3, 6, and 7 and 8, respectively). 
The AP1F oligonucleotide showed a stronger affinity to API than did AP1E (Fig.
13 A  lanes 6, 7, and 8). These results support the specificity of the API sites which 
were weakly protected by nuclear extracts in Fig. 9.
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Fig. 12. The putative API sites of ALTR identified by DNase I footprinting with 
c-Jun/APl. Footprinting was performed as described in MATERIALS AND 
METHODS: 380-bp probe DNA containing the entire 323-bp ALTR was 32P-labelled 
at the 5' end of the upper strand and subjected to competition DNase I footprinting as 
in Fig. 11. Nt sequences of oligonucleotides used are shown in Table 1: sequences of 
Visna API and NF-kB were also described in the legends of Figs. 7 and 8, 
respectively; oligonucleotide AP IF has the ALTR sequence from nt -185 to -209. 
Molar excess of competitors is indicated (400x =14 pmol). According to this 
footprinting result, the putative API sites could be divided into strong binding (A to 
D) or weak binding sites (E and F).
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Fig. 13. The API sites footprinted with c-Jun/APl in 3' half of the U3 region of the 
four EIAV LTRs. DNase I footprinting was performed as described in MATERIALS 
AND METHODS: probe DNAs containing the U3 region downstream of Aht I site 
were 3*P-labelled at the 5' end of upper strands and subjected to DNase I footprinting 
as in Fig. 12. Nt sequences of oligonucleotides used are shown in Table 1: PLTR API 
has the PLTR sequence from nt -45 to -63; APIE has the PLTR sequence from nt 
-139 to -163; Visna API, NF-kB, and AP1F were also described in the legends of 
Figs. 7, 8, and 12, respectively. Molar excess of competitors is indicated (400x = 14 
pmol). Panels A to D were taken from the same gel.
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(3.) Gel Shift Assays of Oligonucleotides of Putative EIAV API Sites with 
c-Jun/APl
Gel shift assays for API sites were performed for the following reasons. One 
reason is to further confirm the specificity o f the footprinted API sites, since there 
have been instances when a factor has been detected by footprinting but not by gel 
shift assays and vice versa (Goodwin, 1990). The other reason is to determine relative 
affinity of the API sites to c-Jun/APl and U937 nuclear extracts.
PLTR API and ALTR APIA to AP1D as well as Visna API formed a 
complex that migrated to the same position on the native polyacrylamide gel (Fig.
14A). When API core sequences of ALTR APIA and AP1B were mutated, the 
mutant oligonucleotides, APlAm and APlBm, did not bind c-Jun/APl (Fig. 14A, 
lanes 6 and 8). However, ALTR APIE whose API site was weakly protected by 
c-Jun/APl (Fig. 12) formed a complex with a very weak intensity compared with 
ALTR API A (Fig. 14B). Although not tested, ALTR AP1F is expected to form a 
very weak complex, since its affinity to c-Jun/APl is weak [3.1.3.6.(2.)]. Therefore, 
footprinting and gel shift assays of ALTR with c-Jun/APl suggest that ALTR APIA
to AP1D are strong in binding c-Jun/APl, but AP1E and AP1F are weak.
(4.) Gel Shift Assays of Oligonucleotides of Putative API Sites with U937 
Nuclear Extracts
PLTR API and ALTR APIA to AP1D, which bound c-Jun/APl strongly (see 
above), were examined with U937 nuclear extracts by gel shift assays (Fig. 15). PLTR 
API, ALTR APIA and AP1B, like Visna API, formed a complex at the same position 
(Figs. 15A to 15C). These 3 API oligonucleotides, like Visna API, bound more to 
TPA-induced nuclear extract than to uninduced nuclear extract (Figs. 15A to 15C,
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Fig. 14. Binding of PLTR API and ALTR APIA to AP1D to c-Jun/APl as 
demonstrated by gel shift assay. Nt sequences of oligonucleotides used are shown in 
Table 1: Visna API and PLTR API, and ALTR AP1E were also described in Figs. 7 
and 13 legends, respectively; API Am and APlBm are the mutants of oligonucleotides 
ALTR APIA and AP1B, respectively (core sequences were mutated from TGACGCA 
and TGACGCG to TTTTGCA and TTTTGCG, respectively); oligonucleotides 
ALTR APIA to AP1D have ALTR sequences, nts -40 to -60, -67 to -86, -108 to 
-126, and -138 to -158, respectively. Lanes 1, 3, 5, 7, 9, 11, and 13 are BSA controls, 
and the other lanes are sample lanes. The gel shift assay (25 |il binding reaction) was 
performed as described in MATERIALS AND METHODS with 1 footprinting unit 
(1.1 (ig) of c-Jun/APl and 32P-labelled probes of 61,000 cpm (24 to 41 finol) in panel 
A or with 55,000 cpm (29 to34 finol) in panel B. The binding reaction was resolved 
on a nondenaturing 6% polyacrylamide gel. The positions of the bound DNA-protein 
complex (Complex) and the unbound freely migrating probe (Free) are indicated.
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Fig. 15. Binding of PLTR API, and ALTR APIA and AP1B to U937 nuclear extracts 
as demonstrated by gel shift assays. Nt sequences of oligonucleotides used are shown 
in Table 1: PLTR API and Visna API, AP1E, AP1F, and NF-kB were also described 
in the legends of Figs. 7, 13, 12, and 8, respectively; ALTR APIA to AP1D were also 
described in the Fig. 14 legend. For each probe, the first, second, and third lanes are 
BSA control, sample with uninduced nuclear extract, and sample with induced nuclear 
extract, respectively. Other lanes are samples with indicated competitor. For each 
sample lane, 8 pg of nuclear extract was used. The gel shift assay (25 pi binding 
reaction) was performed as described in MATERIALS AND METHODS. In each 
panel, probes with the same amount of radioactivity were used. For competition, 3 
pmol of unlabelled oligonucleotide was added 7 minutes before adding probe DNA. 
The 3 pmol of competitor corresponds to 300-fold molar excess of the EIAV LTR 
probes, and to 185- and 250-fold molar excess of the visna LTR probe in panel A, and 
B and C, respectively. The binding reaction was resolved on a nondenaturing 6% 
polyacrylamide gel. The positions of the bound DNA-protein complex (Complex) and 
the unbound freely migrating probe (Free) are indicated.
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lanes 2 and 3). This indicates that they bind to TPA-inducible protein(s) such as API 
[see 1.1.3.5.(3.)]. The 3 API oligonucleotides of EIAV LTR were not competed by 
the weak API site oligonucleotides, ALTR AP1E and AP1F (Fig. 15A lanes 6 and 7), 
nor by the oligonucleotide NF-kB (Figs. 15B and 15C, lanes 6's). However, these 3 
API oligonucleotides were specifically competed by self and Visna API (Figs. 15 A to 
15C, lanes 4 and 5), ALTR AP IB (Fig. 15B, lane 7), PLTR API (Figs. 15B and 15C, 
lanes 8's), and ALTR APIA (Fig. 15C, lane 7). The competition between any of the 3 
EIAV API oligonucleotides and Visna API was not as efficient as competition among 
the 3 EIAV API oligonucleotides themselves (Fig. 15A to 15C). This suggests that 
the 3 EIAV API sites bind different API heterodimers than the consensus API 
sequence.
ALTR AP1C and AP1D did not form a detectable complex with nuclear 
extracts (Figs. 15D and 15E). This suggests that AP1C and AP1D sites have very
different binding specificity for API dimers than the consensus API sequence.
(5.) Determination of the Relative Affinity of the Putative API Sites and 
TPA-induction Level of API Activity
Relative binding affinity of the putative API sites to c-Jun/APl and to nuclear 
extracts, and TPA-induction level of API activity were determined by comparing 
shifted band intensities in the above gel shift assays [3.1.3.6.(3.) and (4.)] as described 
(see 2.12.). The results are summarized in Table 3. The 4-hour TPA treatment of 
U937 cells induced API binding activity in the nuclear extracts about twice (1.5 to 2.3 
folds) (Table 3), which is about half the induced level observed in HepG2 cells (Angel 
et al., 1987). PLTR API, and ALTR APIA and AP1B sites have lower affinities to
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c-Jun/APl but higher affinities to U937 nuclear extracts than visna LTR API site 
(Visna API). It is not clear why these three EIAV API sites were protected only 
weakly in DNase I footprinting with nuclear extracts (Figs. 9A to 9D), in spite of their 
higher affinities to nuclear extracts than that of visna virus LTR API site. It could be 
due to steric hindrance to the API sites of the footprinting probes caused by proteins 
bound on the neighboring sites. Another possibility is that the different conditions in 
footprinting and gel shift assays affected the binding efficiency of the API sequences, 
and therefore, the affinity values. ALTR AP1C and AP1D had higher affinity to
c-Jun/APl than ALTR AP IB, but their affinities to nuclear extracts were negligible.
















RAun 1.0* 0.13 0.36 0.09 0.18 0.28 0.03
RA e 1.0° 2.3 2.6 1.5 0.0 0.0 N.D.
R A pa 2.3 3.4 5.0 3.3 0.0 0.0 N.D.
I nduction ( RA pa/ RA e ) 2.3 1.5 1.9 2.2 N.D. N.D. N.D.
The abbreviations used are: RAJun, relative affinity to c-Jun/APl(Promega); RA,^, 
relative affinity to uninduced U937 nuclear extract; R A ^, relative affinity to 
TPA-induced U937 nuclear extract; N.D., not determined.
Induction (fold) was determined by the ratio of RA^/RA,^.
* The affinity of Visna API to c-Jun/APl measured by radioactivity of the shifted band 
was taken as standard for RAJun.
b The affinity of Visna API to uninduced U937 nuclear extract measured by 
radioactivity of the shifted band was taken as standard for RA^ and RAtpa.
3.2. Functional Characterization of the U3 Region of EIAV LTR
3.2.1. Time Course Analysis of EIAV LTR-directed Luciferase Gene Expression 
in U937 Cells
To determine the condition for detecting maximal luciferase activity in 
transfected U937 cells, a time course experiment was performed. In addition, some 
variables of transfection (effect of freeze-thaw lysis, volume of cell lysis buffer, extent
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of centrifugation, and stability of luciferase activity at 4 °C) were tested. The time 
course experiment was necessary to determine the optimum cell-harvesting time 
because reporter gene expression is dependent on time and the cell type used. For 
example, peak expression times of reporter enzymes such as luciferase and 
chloramphenicol acetyltransferase can be very different for a specific cell type (Brasier, 
1990; Pahl et al., 1991). Harvesting at peak expression time can be a solution to 
difficulties in promoter studies due to low promoter activity, low transfection 
efficiency, and low-sensitivity assay equipment, etc. Fig. 16 shows a sharp peak and a 
very high luciferase activity for both uninduced and TPA-induced samples 8 hour after 
transfection. Based on this data, the cell-harvesting time for the present study was 
determined to be 8 hour post-transfection. This peak time was chosen because 
promoter activity of EIAV LTR has been found to be extremely low (Carvalho and 
Derse, 1993a) and because only scintillation counters were available to assay the 
reaction instead of a more sensitive luminometer. To remove any variation due to 
different electroporation efficiencies, all the separately electroporated cells were 
combined, mixed, and then distributed.
The variables mentioned above were tested as below, (i) Effect of ffeeze-thaw 
lysis on luciferase activity: among the lysis methods for transfection assay, repeated 
ffeeze-thaw lysis has been described as a standard method in luciferase assay (Brasier, 
1990; Docherty and Clark, 1993). Along with the time course study, one uninduced 
sample at the 16 hour-time point was prepared by 2 cycles of fireeze-thaw lysis. This 
sample had a very low luciferase activity of 30 kcpm/p.g protein which was just above
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■  ind(xO.l)
8 8 M S
8 12 16 
Hours post-transfection
Fig. 16. Time dependence of luciferase activity in transfected U937 cells. U937 cells 
were electroporated with EIAV ALTR luciferase plasmid (pALTRLuc). Multiple 
electroporations were combined and distributed for incubations indicated five (4, 8,
12, 16, and 24 hours) and four (8, 12, 16, and 24 hours) time points for uninduced and 
induced U937 cells, respectively. For induction, 30 nM TP A was added. Cells 
incubated for the indicated times were harvested, and luciferase activity was measured 
as described in MATERIALS AND METHODS.
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buffer blank level. In another experiment, the freeze-thaw lysis was again found to be 
deleterious to luciferase activity: all the uninduced samples prepared by the 
freeze-thaw lysis at 6, 12, and 24 hour-time points had only slightly higher activities 
than that of the buffer blank, (ii) Volume of cell lysis buffer did not affect the 
transfection result: 200 pi and 300 pi of lysis buffer led to the same specific luciferase 
activity expressed as kcpm/ pg protein, (iii) Centrifugation effect: lysis procedures 
usually include a brief centrifugation to remove cell debris after cell lysis. The pellets 
were found here to be easily swollen and detached from the microfiige tube wall, 
causing a decrease in the measured luciferase activity. In a separate experiment with 4 
different EIAV constructs, an additional 10 minute centrifugation could increase 
luciferase activity about 35%. In another experiment, when 0.003% and 0.03% 
portions of a pellet which were dissolved in RLB (Promega) containing 1 mg/ml BSA 
and freeze-thawed once were added to 2 pi of 8-hour time point samples (cell 
extracts), the luciferase activity was decreased to about 90% and 50%, respectively. 
This implies that contamination of luciferase samples by 0.5% portion of a pellet can 
result in 10% reduction in luciferase activity, (iv) Stability of luciferase at 4 °C: when 
uninduced luciferase samples were incubated on ice for about 1.5 hour, luciferase 
activities were increased to about 150%, but further incubation at 4 °C for total 16 
hour decreased the activities to about 15% and 25% of the original activities in 
uninduced and induced samples, respectively. Another point to be considered in 
luciferase assays was that static charge could make a serious problem. For example, 
empty vials rubbed with latex gloves had up to about 1 million cpm. This problem was
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solved after handling the vials without latex gloves and placing the sample vials in 
contact with a metal conductor before inserting them into a scintillation counter for 
counting.
3.2.2. Functional Characterization of Transcription Factor Binding Sites in the
U3 Region of EIAV LTR
Functional characterization was performed by luciferase assays using 
uninduced and TPA-induced U937 cells transfected with luciferase plasmids 
containing intact or mutated EIAV LTRs. TP A treatment induces U937 monocytic 
cells to mature into macrophages in which EIAV can replicate. Thus, it is more 
important to compare TPA-induced promoter activity than to compare uninduced 
promoter activity.
3.2.2.I. Putative EIAV NRE Region (nts -135 to -181 of ALTR)
The progressive internal deletions covering most of the U3 region (Fig. 17), 
except the most upstream deletion of the region from n t-135 to -181, significantly 
reduced promoter activity to 40%-64% and 22%-49% of wild-type levels in uninduced 
and TPA-induced U937 cells, respectively (Fig. 18A). The most upstream deletion 
slightly enhanced the promoter activity to 114% and 128% of wild-type levels in 
uninduced and TPA-induced U937 cells, respectively (Fig. 18 A). If deletion of 
positively-acting Oct-1 element (see 3.2.2.2.) in pD(-135/-181)Luc is considered, the 
deleted portion of the construct may contain an NRE sequence. Because the deletion 
from nt -135 to -181 mutates both Oct-1 and NRE, and the deletion from nt -118 to 
-137 mutates Oct-1 only, the NRE effect may be directly calculated using 
pD(-l 18/-137)Luc as control for pD(-135/-181)Luc. Then, deletion of NRE only may

























pD( — 31/ — 46)LucTTT
pALTR(APlBm)Luc TTT
pALTR(APlAm)Luc
Fig. 17. The six internal deletions and two site-specific mutations of ALTR. Only part of the ALTR sequence is shown here with the 
transcription factor binding sites which could bind U937 nuclear extracts, while the entire sequence in Fig. 5A. The APIA and AP1B 
sites were named in Fig. 12, and PU. 1A and PU. IB sites here for the downstream and upstream PU. 1 sites, respectively, of ALTR in 
Fig. 9B. The deleted nt sequences of the deletion mutants are indicated by the broken lines with the mutant names beneath them. The 
three nts TTT, which were changed from GAC, of the site-specific mutants are indicated above the mutant names. The arrow 
indicates the transcription initiation site (+1). For other symbols, see Fig. 5 legend. The mutants were made from the pALTRLuc as 
described in MATERIALS AND METHODS.
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Fig. 18. Luciferase assays of U937 cells transiently transfected with luciferase repoter 
plasmids containing ALTR mutants (panel A) and the four EIAV LTRs (panel B). 
Luciferase assays were performed as described in MATERIALS AND METHODS. 
Luciferase activity is indicated as kcpm per pg protein of cell extract and as 
percentage of the activity determined for pALTRLuc in uninduced (average 1,419 
kcpm/pg protein) and TPA-induced (average 11,544 kcpm/pg protein) U937 cells, 
respectively. The results represent the averages of three independent determinations ± 
standard errors of the mean. Mean of luciferase activity is shown at the end of the bar 
and number of fold induction in parenthesis. For visna LTR luciferase plasmid, 
pVTSLTRLuc, luciferase activity per 0.1 pg protein was plotted. pGL2-Enhancer 
Vector contains an SV40 enhancer of the SV40 early promoter, and pGL2-Control 
Vector contains the SV40 promoter and enhancer sequences. All other luciferase 
plasmids were constructed by inserting an LTR sequence into the same polylinker site 
of pGL2-Enhancer Vector: pVTSLTRLuc contains a portion of visna LTR from nt 
-140 to nt +27; Plasmids, pPLTRLuc, pV470LTRLuc, pV3291LTRLuc, and 
pALTRLuc contain a full-length EIAV LTR; pD(-135/-181)Luc to pD(-3 l/-46)Luc 
are the deletion mutants of pALTRLuc; pALTR(APlBm)Luc and 
pALTR(APlAm)Luc are the API site site-specific mutants of pALTRLuc. Results of 
panels A and B were from the same assays.
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enhance the promoter activity to 228%(=114/50), 337% (=128/38) of wild-type 
ALTR levels in uninduced and TPA-induced U937 cells, respectively.
NRE effect in transcription might be less prominent in macrophage cells like 
TPA-induced U937 cells as shown here than in nonmacrophage cells, and thus EIAV 
NRE might contribute in viral replication in macrophage cells compared with 
nonmacrophage cells. Interestingly, the region from nt -136 to -150 of ALTR has 
60% sequence homology to HIV-1 NRE (5' C ATTTC ATC AC AT GG 3': Nabel, 1993, 
where nts identical to those of EIAV LTR are underlined). This also suggests that 
NRE might reside upstream of nt -135 of ALTR.
Previous studies which defined EIAV NREs (Dorn and Derse, 1988; Sherman 
et al., 1989) showed that the activity of NREs is critically dependent on the cell type 
used. Feline and canine fibroblastic cells were used in these studies [see l.l.3.6.(l.)]. 
In this regard, the use of macrophage cells of TPA-induced U937 in the current study 
should be more relevant. However, the NRE region found in the current study needs 
to be examined further.
3.2.2.2. Putative EIAV Oct-I Region (nts -125 to -144 of ALTR)
Deletion of the region from nt -118 to -137 in ALTR (Fig. 17) reduced basal 
promoter activity to 50% and 38% of wild-type levels in uninduced and TPA-induced 
U937 cells, respectively (Fig. 18A). This suggests that the EIAV Oct-1 site is a 
positively-acting element in transcriptional initiation. This conclusion is also supported 
by the following observation. ALTR and V470LTR have very similar U3 sequences 
(Figs. 5A and 5B) except for the Oct-1 site. Single-base differences in both API and
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PU. 1 sites centered at -54 and -66, respectively, of these two LTRs did not make any 
change in their footprints (Figs. 9B and 9C). Thus, V470LTR can be considered as an 
Oct-1 site site-specific mutant of ALTR. Similar to the Oct-1 site deletion mutant, 
V470LTR had reduced promoter activities: 66% and 41% of ALTR levels in 
uninduced and TPA-induced U937 cells, respectively (Fig. 18B). However, this 
putative Oct-1 site seems to be nonessential for EIAV replication, since this site could 
be protected only in ALTR. But this Oct-1 site might be related, by increasing 
promoter activity, to the high cytopathogenicity (Rasty et al., 1990) of AFDD EIAV.
Carvalho and Derse (1993 a) identified in the PLTR a different octamer site 
overlapping with the PU.l site and API site centered at -42 and -53, respectively. 
Binding of this octamer site to nuclear extracts was detected by gel shift assay when 
PU. 1 binding to the overlapping PU. 1 site was inhibited. More specific study is 
necessary to unravel the function of this octamer site. However, two EIAV LTRs 
without an octamer motif have been reported, which were isolated from macrophage 
cells matured from horse monocytes infected with an EIAV field isolate (Maury,
1994). Therefore, this octamer site centered at nt -46 of ALTR also appears to be 
nonessential in EIAV replication.
3.2.2.3. EIAV MDBP Region (nts -94 to -114 of ALTR)
Deletion of the region from nt -101 to -117 in ALTR reduced basal promoter 
activity to 48% and 49% of wild-type levels in uninduced and TPA-induced U937 
cells, respectively (Fig. 18 A). This suggests that the EIAV MDBP site is a 
positively-acting element in transcriptional initiation.
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Essentially, there has been no functional studies on EIAV MDBP site before. 
Although it is for Tat-transactivated promoter activity in uninduced nonmacrophage 
cell lines, Carvalho and Derse (1993a) observed that the deletion from -76 to the 5' 
end of PLTR reduced promoter activity to 62% and 42% of wild-type levels in D17 
and HeLa cells, respectively. But the same deletion resulted in increase in basal and 
Tat-transactivated promoter activity in uninduced FEA cells 29 and 2.5 folds, 
respectively (Dorn and Derse, 1988). Even this long deletion destroyed, in addition to 
MDBP site, its flanking PEA2 site and possibly upstream elements, if any. Thus, more 
specific mutation studies are needed to detail the function of EIAV MDBP sequence.
3.2.2.4. EIAV PEA2 Region (nts -76 to -99 of ALTR)
Since I have not examined any mutation effect for PEA2 sites, it is not known 
how the PEA2 sites function in transcriptional regulation in U937 macrophage cells. 
Carvalho and Derse (1993a) showed that the tandem-repeated PEA2 sites are 
positively-acting, dispensable individually, and orientation-independent transcriptional 
regulatory elements by assaying Tat-transactivated promoter activity in uninduced D17 
cells. The positively-acting property of PEA2 site was also observed in THP-1 cells 
(Carvalho and Derse, 1993b) [1.1.3.6.(3.)]. However, since oligonucleotide 
containing the most upstream PEA2 site could not be retarded by gel shift assay with 
nuclear extracts of macrophages matured from horse monocytes (Maury, 1994), the 
PEA2 sites seems to be nonfunctional in horse macrophages, and therefore, 
nonessential in EIAV replication.
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3.2.2.5. Putative EIAV C/EBP Binding Site (nts -16 to -24 of ALTR)
Since I have not examined any mutation effect for this putative C/EBP site, it is 
not known how this site functions in transcriptional regulation in macrophage cells.
It has been shown that expression of NF-IL6 (C/EBP-3), a member o f C/EBP 
family, is associated with the differentiation of monocytes/macrophages (Akira and 
Kishimoto, 1992; Freytag and Geddes, 1992; Umek et al., 1991). Thus, the putative 
EIAV C/EBP site might play a role in viral replication during the differentiation of 
monocytes/macrophages.
3.2.2.6. EIAV PU.l Regions (nts -31 to -47, and nts -59 to -70 of ALTR)
PU. 1 function was examined using the three deletion mutants, pD(-3 l/-46)Luc, 
pD(-43/-57)Luc, and pD(-61/-77)Luc, along with the two API site site-specific 
mutants, pALTR( API Am)Luc and pALTR(APlBm)Luc (Fig. 17). Deletion of the 
PU. 1A site [pD(-3 l/-46)Luc] reduced the promoter activity to 64% and 33% of 
wild-type levels in uninduced and TPA-induced U937 cells, respectively (Fig. 18A). 
This indicates that the PU. 1A site acts positively in transcriptional initiation in both 
monocytes and macrophages, and that the presence of the PU. 1A site is more 
important for the promoter activity in macrophages than in monocytes. When both the 
PU. 1A and APIA sites were deleted together [pD(-43/-57)Luc], promoter activity 
was further reduced, indicating that the PU. 1A and APIA sites cooperate for the 
maximal promoter activity. This is the same case for the PU. IB and AP1B sites.
When the AP1B site alone was mutated [pALTR(APlBm)Luc], promoter activity was 
reduced to 95% and 56% of wild-type levels in uninduced and TPA-induced U937
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cells, respectively. When the APIB and PU.IB sites were deleted together 
[pD(-61/-77)Luc], promoter activity was further reduced to the levels similar to those 
of pD(-43/-57)Luc, indicating that the PU.IB site is also a positive regulator in 
transcriptional initiation, though this PU. 1 site appeared to bind weaker than the 
PU.l A site (Fig. 9B). These data indicate that the PU.l sites are positively-acting but 
dispensable individually for uninduced and TPA-induced basal promoter activities.
The dispensability of the PU. 1A site is particularly noticeable because all the EIAV 
isolates so far reported have a PU. 1 site at the position of PU. 1A site (Carpenter et al, 
1991; Carvalho et al, 1993; Maury, 1994). These data also confirm the observation by 
Maury (1994) that PU.l mutation did not significantly reduce basal promoter activity 
in uninduced primary horse macrophage cells.
3.2.2.7. EIAV API Regions (nts -51 to -57, and nts -71 to -77 of ALTR)
It has been found that if cells are induced by TP A or PKC activators, the 
composition of API complex shifts from dimers of mainly Jun family members to 
mostly Jun/Fos heterodimers (Karin, 1991). Thus, it has been suggested that c-Jun 
homodimers are responsible for the maintenance of basal level of transcription while 
Jun/Fos heterodimers are mostly involved in initiating the induction response (Karin, 
1991). This suggests that API sites in ALTR AP1C and AP1D might be functional in 
cells of uninduced state. However, these two sites did not bind even the uninduced 
U937 nuclear extracts. Thus, AP1C and AP1D sites seem to be nonfunctional in 
U937 macrophages, and are not discussed further.
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When the APIA site was site-specifically mutated [pALTR(APlAm)Luc], the 
promoter activity was, as in the deletion of PU.l A site, significantly reduced to 63% 
and 45% of wild-type levels in uninduced and TPA-induced U937 cells, respectively 
(Fig. 18 A). This indicates that the APIA site acts, like PU.l A site, positively in 
transcriptional initiation and its presence is more important for promoter activity in 
macrophages than in monocytes. Simultaneous deletion of the API A and PU. 1A sites 
[pD(-43/-57)Luc] resulted in still lower promoter activity of the API A site 
site-specific mutant [pALTR(APlAm)Luc] (Fig. 18A). This indicates that there is a 
cooperativity between the API A and PU.l A sites for the promoter activity. The same 
cooperativity phenomenon was observed between the APIB and PU.IB sites, 
although AP1B site contributes relatively less to the promoter activity than APIA site 
(Fig. 18 A). The reduced promoter activities of the API site site-specific mutants 
indicate that both API sites are important in macrophage cells, though either APIA or 
AP1B site is dispensable. Since I have not examined a double mutation of both API 
sites, the total effect of API sites on the promoter activity in macrophage cells is not 
known. It has been previously observed that when the only API site in PLTR was 
mutated, Tat-transactivated promoter activity was greatly reduced to less than 15% of 
its wild-type level in uninduced D17 and HeLa cells (Carvalho and Derse, 1993a) or to 
about 50% of its wild-type level in uninduced THP-1 cells (Carvalho and Derse,
1993b), implying that the API site plays an important role in EIAV replication.
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3.2.2.8. Activation of the EIAV LTR Promoter by TPA
The 8-hour TPA treatment of the U937 cells transfected with the series of 
ALTR luciferase reporter plasmids resulted in an induction in the range of 4.2- to 
9.1-fold (Fig. 18 A). The TPA responsiveness of a specific element can be derived by 
comparing the induction level of a mutant with that of the wild type (Carvalho and 
Derse, 1993a). Deletion of PU. 1A site [pD(-3 l/-46)Luc] reduced the TPA induction 
most significantly from 8.1-fold of pALTRluc to 4.2-fold. Mutations of the API B and 
APIA sites reduced the TPA induction from 8.1-fold to 4.8-fold and 5.8-fold, 
respectively. The deletions of Oct-1 [pD(-l 18/-137)Luc] and MDBP 
[pD(-101/-l 17)luc] sites changed the TPA induction from 8.1-fold to 6.3-fold and 
8.4-fold, respectively. Thus, the TPA induction of the wild type pALTRLuc results 
partly from the positive contribution of the elements in the descending order of 
PU.l A, AP IB, APIA, and Oct-1, from no contribution of MDBP, and from the 
negative contribution from the NRE. The negative contribution of the NRE is clear if 
pD(-118/-13 7)Luc is considered as the control of pD(-13 5/-181 )Luc. The 
contribution from other sites (PU.IB and PEA2 sites) is not known accurately because 
of no examination of appropriate mutants. The small effect of the PU. 1A site deletion 
of ALTR on the TPA induction in the absence of Tat in U937 cells here is in contrast 
with the huge effect of the PU. 1 site mutation of PLTR on the TPA induction in the 
presence of Tat in HeLa cells (Carvalho and Derse, 1993a).
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3.2.2.9. Variant EIAV LTRs
The promoter activity of the 4 EIAV LTRs is about 10 times weaker than that 
of the visna virus LTR construct (pVISLTRLuc) (Fig. 18B). The 4 EIAV LTRs have 
different structures between nt -38 to -140 (Fig. 5B), especially in the hypervariable 
region marked by the lines over the elements (e.g., between the APIA and upstream 
PEA2 sites of ALTR) in Fig. 5B. The hypervariable region of the 4 EIAV LTRs has a 
combination of PEA2, API, and PU.l motifs. Although the promoter activity of 
ALTR and V470LTR can be compared directly as in 3.2.2.2., comparison among the 4 
LTRs appears to be difficult and needs specific mutational analyses.
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CHAPTER 4 
SUMMARY AND CONCLUSIONS
In this dissertation, the U3 region of EIAV LTR was characterized physically 
and functionally. Several transcription factor binding site(s) of the U3 region of 
prototype (P), fetal donkey dermal cell-adapted (A), and two variant (V) EIAV LTRs 
were localized by DNase I footprinting using TPA-induced and uninduced U937 cell 
nuclear extracts. (1) A putative Oct-1 site was localized in the 5' half of the U3 region 
of ALTR but not of the other 3 LTRs. (2) A putative MDBP site was localized in the 
5' half of the U3 region of the 4 LTRs. This was the first MDBP footprint ever 
observed in EIAV LTR. (3) One or two putative PEA2 sites were localized in the 
middle of the U3 region of the 4 LTRs. (4) One or two putative AP1 sites were 
localized in the region from nt -40 to -80 of the U3 region of the 4 LTRs. (5) One to 
three putative PU. 1 sites were localized in the region from nt -30 to -90 of the U3 
region of the 4 LTRs. There are 5 different PU. 1 sequences among 8 footprinted 
PU. 1 sites. Among the 5 different PU. 1 sequences, two of them have not been 
previously described. (6) A putative C/EBP site which partly overlaps with the TATA 
box was localized in the U3 region of the 4 LTRs. This EIAV C/EBP element is 
described for the first time. Results from both DNase I footprinting of the 4 LTRs and 
gel shift assays of oligonucleotides containing LTR API sites using purified human 
c-Jun/APl protein, and results of gel shift assays of the oligonucleotides using U937 
nuclear extracts supported the localization of the putative AP 1 sites in the region from 
nt -40 to -80.
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For the functional characterization of the U3 region of EIAV LTRs, both the 6 
internal deletion mutants and the 2 API site site-specific mutants of ALTR were 
examined along with the wild-type constructs of the 4 EIAV LTRs by the transient 
gene expression luciferase assays using TPA-induced and uninduced U937 cells. The 
basal promoter activity was measured by these assays. (1) The putative NRE, 
identified by the transient gene expression assays, appears to reduce uninduced and 
TPA-induced promoter activityties of the U3 region about 2-, and 3-fold, respectively. 
(2) The putative Oct-1 site of ALTR appears to act positively in transcriptional 
initiation. This site might be involved in the high pathogenesis of the 
ALTR-containing FDD cell-adapted EIAV by increasing the promoter activity of 
LTR. (3) The putative MDBP site appears to act positively in transcriptional 
initiation. (4) The function of the putative PEA2 sites was not studied in this study.
But the PEA2 motif has been found not to bind nuclear extracts of primary horse 
macrophages, suggesting that the PEA2 sites may be nonfunctional in horse 
macrophages (Maury, 1994). (5) The putative API sites act positively in 
transcriptional initiation. (6) The PU. 1 sites act positively in transcriptional initiation.
The tested transcription factor binding sites of EIAV LTR except NRE appear 
to act positively in transcriptional initiation in both TPA-induced and uninduced U937 
cells. The Oct-1, API, and PU. I elements appear to be more important in 
TPA-induced basal promoter activity. Among these 3 elements, the PU. 1 element acts 
most strongly for basal promoter activity in TPA-induced U937 cells, implying the 
importance of PU. 1 sites in macrophages. The PU. 1 sites appear to respond most
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strongly to the TPA induction. In addition, the two PU. 1 sites appear to cooperate 
with the two API sites to increase the promoter activity. Therefore, PU. 1, API, 
MDBP, and Oct-1 act cooperatively for maximal basal promoter activity in both 
TPA-induced and uninduced U937 cells.
The function of the putative EIAV C/EBP site has not been studied. Any 
future studies will have to find the function of this site in viral replication during the 
differentiation of monocytes/macrophages.
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AGID Agar gel immunodiffusion.
AIDS Acquired immunodeficiency syndrome.
ALTR FDD cell-adapted (AFDD) EIAV LTR.
AP-1 A synonym of API.
API Activator protein 1.
ATP Adenosine triphosphate.
BCA Bicinchoninic acid.
BIV Bovine immunodeficiency virus.
BLV Bovine leukemia virus.
bp base pair.
BSA Bovine serum albumin.
C-ELISA Competitive enzyme-linked immunosorbent assay.
CA Capsid protein.
CAEV Caprine arthritis-encephalitis virus.
CAT Chloramphenicol acetyltransferase.
CC-CKR-5 Cysteine-cysteine chemokine receptor 5.
cDNA complementary DNA.
CIAP Calf intestinal alkaline phosphatase.
CKR-2B Chemokine receptor 2B.
CKR-3 Chemokine receptor 3.
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COUP-TF Chicken ovalbumin upstream promoter transcription factor. 
CPE Cytopathic effect.
CTF CAAT transcription factor.
DNA Deoxyribonucleic acid.
DNase Deoxyribonuclease.









EF-C Enhancer binding factor to polyoma element C.
EIA Equine infectious anemia.
EIAV Equine infectious anemia virus.
EP Factor binding to region EP of hepatitis B virus enhancer.
ER Endoplasmic reticulum.
EtBr Ethidium bromide.
FCS Fetal calf serum.
FDD cell Fetal donkey dermal cell.
FEK Fetal equine kidney.
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FTV Feline immunodeficiency virus.
HEPES Ar-2-hydroxyethylpiperazine-Ar-2-ethanesulphonic acid.
m v Human immunodeficiency virus.
HIV-1 HIV type 1.
HMC Horse macrophage culture.
HTLV Human T-cell leukemia (or lymphotropic) virus.
HTLV-I HTLV type I.




LB medium Luria-Betani medium.
LBP-1 Leader binding protein 1.
LSU SVM Louisiana State University School of Veterinary Medicine.
LTR Long terminal repeat.
M-tropic Macrophage-tropic.
MA Matrix protein.
MDBP Methylated DNA-binding protein.
MEF Myc intron factor.
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NF-1 Nuclear factor 1.
NF-A1 Nuclear factor A1.
NF-AT Nuclear factor of activated T cell.
NF-JB Nuclear factor binding to JB element.
NF-kB Nuclear factor of kappa B cells.
NFm Nuclear factor EH.
NRE Negative regulatory element.
nt Nucleotide.
OBP100 Octamer binding protein of 100 kDa.
ORF Open reading frame.
OTF-1 Octamer-binding transcription factor 1.
PBS (1) Primer binding site. (2) Phosphate-buffered saline.
PCR Polymerase chain reaction.
PEA2 Polyoma enhancer A binding factor 2
(or polyomavirus enhancer A binding protein 2).
PEA3 Polyomavirus enhancer A binding protein 3.
PEBP2 Polyomavirus enhancer binding protein 2.
PKC Protein kinase C.




Rev Regulator of expression of virion proteins.
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RF-X Regulatory factor binding to X box.
RFX Synonym of RF-X.




RPMI medium Roswell Park Memorial Institute medium.
RRE Rev response element.
RSV Rous sarcoma virus.
RT Reverse transcriptase.
SDS Sodium dodecyl sulfate.
SFFV Spleen focus forming virus.
Sfpi-1 SFFV proviral integration site-1 binding pi
SIV Simian immunodeficiency virus.
Spi-1 SFFV proviral integration site-1 binding pi
ss single-stranded.
SS DNA Salmon sperm DNA.
STLV Simian T-cell leukemia virus.
SU Surface protein.
SV40 Simian virus 40.
T-tropic T cell line-tropic.
TAF TBP-associated factor.
TAF110 110-kDa TAF.
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TAF250 250-kDa TAF.
TAR /rans-activation responsive element.
TBE 89 mM Tris base/89 mM boric acid/2.5 mM EDTA.
TBP TATA-binding protein.
TCF-la T-ceU factor la .
tdt Terminal deoxynucleotidyl transferase gene.
TE (pH 7.6) 10 mM Tris-Cl, pH 7.6/1 mM EDTA, pH 8.0.
TE (pH 8.0) 10 mM Tris-Cl, pH 8.0/1 mM EDTA, pH 8.0.
TFH-I Transcription factor II-I.
TFUD Transcription factor HD.
TM Transmembrane protein.
TP A 12-0-tetradecanoylphorbol-13 -acetate.
TRE TPA response element.
tRNA transfer RNA.
Tris Tris(hydroxymethyl)aminomethane.
TRP TAR RNA-binding protein.
TRP-185 185 kDa TRP.
UBP Untranslated binding protein.
UBP-1 UBP 1.
UBP-2 UBP 2.
USF Upstream binding/stimulatory factor.
V470LTR LTR of pV470LTR i.e., VLTR derived from cDNA 470.
V3291LTR LTR of pV3291LTR i.e., VLTR derived from cDNA 3291
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
156
Vif Virion infectivity factor.
VLTR Variant EIAV LTR.
Vpr Viral protein R
Vpu Viral protein U.
YY1_________Yin and Yan 1._______
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APPENDIX 2 
CELL LINES AND PRIMARY CELLS
Cf2Th cells A canine fetal thymus fibroblastic cell line.
D17 cells A canine osteosarcoma cell line.
equine 6288 cells Equine fibroblast cells.
FDD cells Primary fetal donkey dermal cells.
FEA cells A feline embryo fibroblast cell line.
FEK cells Primary fetal equine kidney cells.
HeLa cells A human epithelial carcinoma cell line.
NIH3T3 cells Mouse whole embryonic cells.
Raji cells A human B cell line.
THP-1 cells A human monocyte cell line.
U937 cells A human monocvtic cell line.
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